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Preface 
One of the major paradigms in structural biology, according to which a rigid well-
folded 3D structure is required for protein function, has clearly changed over the last decades. 
Recent studies show that some proteins despite the absence of a stable secondary or tertiary 
structure, play important roles in a number of biological processes, such as differentiation, 
transcription regulation, DNA condensation, mRNA processing, and apoptosis. Such proteins 
are known as intrinsically disordered proteins (IDPs) and are characterized by high flexibility 
and plasticity, that facilitate their interactions with a broad range of binding partners, such as 
proteins, membranes, nucleic acids and other molecules of biological relevance. (Uversky & 
Dunker, 2010). Intrinsically disordered proteins are also prone to misfolding and tend to 
evade normal clearance pathways. In turn, the combination of misfolding and lack of clearing 
mechanisms can result in aberrant processes, often associated with the onset of pathologies. In 
these cases, it is common to observe progressive protein aggregation into intracellular and/or 
extracellular deposits. The consequence is a diverse group of neurodegenerative disorders, 
each of which entails the aggregation of particular proteins in characteristic patterns and 
locations (Jucker & Walker, 2013). 
Under some particular conditions (e.g. environmental change or mutation) even native 
folded proteins might lose theirs stable, biochemically functional forms, and for this reason 
they can be investigated by the same methodologies used for IDPs. Examples of such proteins 
are beta amyloid peptide (Aβ) (intrinsically disordered in the monomeric form) associated to 
the Alzheimer’s disease (AD), and superoxide dismutase (SOD1) (which is intrinsically 
disordered in the reduced apo form) related to amyotrophic lateral sclerosis (ALS). These 
proteins are the main topics of this thesis.  
In this work we will present detailed structural characterization of Aβ prefibrillar and 
fibrillar assemblies by Solid State Nuclear Magnetic Resonance (SSNMR) that is crucial for 
understanding Aβ precise mechanism aggregation pathways and identifying toxic Aβ species 
involved in Alzheimer’s disease.  
This thesis will demonstrate also attempt of reverting side effects caused by cisplatin, 
that is effectie drug strongly inhibiting process of SOD1 oligomerization. That could open a 
way toward a novel therapeutic strategies in amyotrophic lateral sclerosis (ALS), since the 
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clinical use of cisplatin is still limited cause of the development of neurotoxicity and others 
undesirable effects. 
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Chapter 1   Introduction 
 
1.1 Neurodegenerative diseases. Protein folding and misfoding 
Neurodegenerative diseases are defined as hereditary and sporadic conditions that 
leads to progressive dysfunction of nervous system. Progression in atrophy of the affected 
central or peripheral structures of the nervous system is slow and steady, with symptoms 
visible when many cells degenerate and die or fail to function properly. According to their 
phenotypic effects they can be divided into two subclasses: one related to problems with 
movements, and another one linked with deterioration of the memory, leading to dementia. 
These subclasses encompass such diseases as Alzheimer's disease and other dementias, brain 
cancer, degenerative nerve diseases, encephalitis, epilepsy, genetic brain disorders, head and 
brain malformations, hydrocephalus, stroke, Parkinson's disease, amyotrophic lateral sclerosis 
(ALS or Lou Gehrig's Disease), Huntington's disease, prion diseases and Hallervorden–Spatz 
disease. 
Many of the well-known neurodegenerative diseases represent a set of proteinopathies. 
A common pathological feature of these neurodegeneration is deposition within neurons or in 
the brain parenchyma of pathogenic aggregates. These deposits are composed largely of 
misfolded specific proteins, in the form of amyloid fibrils or plaques, and seem to be directly 
related to neurotoxicity. Protein deposition diseases can be sporadic (85%), hereditary (10%) 
or transmissible (5%). The general principle of these disorders arise from the failure of a 
specific peptide or protein to adopt its native physiological function by changing their 
conformation, size or their three-dimensional shape resulting in self-association, elongation 
and precipitation in distinct brain areas. As a consequence of misfolding, the protein 
aggregates, losses native functions and becomes pathologically active. The risk of self-
association and aggregation is associated with a genetic defect, aging, persistently high 
concentrations of the protein and it is greatly increased with proteins characterized by a high 
level of intrinsic disorder, that facilitates radical changes in their conformation (Bayer, 2013; 
Carrell & Lomas, 1997; Uversky, 2010). 
Although progress in neuroscientific research is noticeable in the substantial 
understanding of the molecular bases of this devastating diseases, still the main question - 
what is the cause of neurodegeneration and how we cope with it? - remains unclear. 
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1.1.1 From Alzheimer’s Disease to amyloid-β 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder named after the 
German physician Alois Alzheimer who first described the disease (Alzheimer, 1907).  
A major pathological feature of AD is the accumulation of two types of proteinaceous 
inclusions: extracellular amyloid deposits – senile plaques in the cerebral cortex and 
vasculature – and intracellular neurofibrillary tangles in medial temporal lobe. Neurofibrillary 
tangles are composed of hyperphosphorylated tau (Grundke-Iqbal et al. 1986), while amyloid 
plaques contain in 90% the amyloid β-peptide (Aβ) (Glenner & Wong, 1984; Masters et al. 
1985). The remaining 10% of amyloid plaques are composed of proteins from the 
apolipoprotein E class, lipids from membranes of degenerated portions of the 
intercommunicated nerve extensions called axons, metal ions such as Cu (I /II), Zn (II), Fe (II 
/III) and Al (III), and traces of other components from the extracellular liquid. Amyloid 
plaques fall into two broad morphological categories: diffuse and neuritic. Both plaque types 
are detectable with anti-Aβ antibodies, but only neuritic plaques are prominently stained by 
sheet-binding dyes such as Congo red and thioflavin S. Neuritic dystrophies are swollen and 
distorted processes of axonal or dendritic origin that radiate from the core of a neuritic plaque. 
They are detectable with antibodies against the amyloid precursor protein (APP), phospho-
tau, neurofilaments and ubiquitin, indicating a disruption of protein transport and attempts to 
degrade this blockage. Progressive neuritic plaque deposition is a hallmark of AD. Neuritic 
plaque formation commonly begins in the neocortex and later affects the hippocampus and 
amygdala. By the end stage of the disease, neuritic plaques are present in the brainstem and 
other subcortical structures. It has been suggested that the presence and a substantial increase 
in diffuse plaque is associated with the preclinical stages of AD. 
Surprisingly, amyloid plaques have been also found in cognitively normal individuals, 
where plaque burden does not correlate with memory decline. Although asymptomatic elderly 
people develop amyloid plaques, the quantity of amyloid is generally less than in AD patients 
(Aizenstein et al. 2008). This unexpected observation that Aβ is produced constantly 
throughout life as a physiologically normal metabolite generated in healthy people changed 
the common concept of AD (Hardy & Selkoe, 2002).  
Several genetic factors have been found to be associated with AD. Missense mutations 
in the genes which encode for amyloid precursor protein, presenlin-1, presenlin-2 have been 
found to be linked with familial Alzheimer’s disease. These observations led to the so-called 
“amyloid cascade hypothesis” (fig. 1), which proposes that the deposition of Aβ, principally 
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of Aβ42, that has a high tendency to aggregate by forming beta-sheet structures, would be the 
central trigger of the pathological changes observed in the brains of AD patients (Hardy & 
Higgins, 1992; Herrup, 2010). The amyloid cascade hypothesis proposes that accumulation in 
the brain of Aβ aggregates lead to a series of downstream events such as loss of neurons and 
white matter, oxidative and inflammatory damage, the cascade of tau-hyperphosphorylation,  
increased cytoskeleton flexibility, which in turn lead to energy failure and synaptic 
dysfunction and neuronal death.  
Although the direct involvement of Aβ peptides in AD is well documented, the precise 
molecular mechanism of the neurotoxic effects and the mechanism of generation and 
oligomerization of Aβ peptides remains unclear. Moreover, there is still a significant gap 
between the site-specific structural information and the complex structural diversity of Aβ 
amyloids. All these uncertainties complicate identifying therapeutic targets for AD and cause 
that this disease is relentless and incurable. The current limited number of treatments for 
Alzheimer's disease merely address symptoms rather than the root causes. 
 
 
 
 
Figure 1. Pathological cascades hypothesis and potential biomarkers of AD. Adapted from 
(Anoop et al. 2010).  
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1.1.2 Pathology of ALS and implication to hSOD1 
 
Amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease) is a neurodegenerative 
disorder characterized by the progressive dysfunction and degeneration of upper and lower 
motor neurons, which results in fatal paralysis. 
The occurrence of ALS is predominantly (90%) sporadic without an obvious etiology. 
Approximately 10% of cases are referred as familial (fALS) and are inherited in a dominant 
manner. In 1993 it was suggested by the first time link between fALS and mutations in the 
gene that encodes the antioxidant enzyme copper-zinc superoxide dismutase (Rosen, 1993), 
and over 100 fALS-linked mutations, distributed throughout the SOD1 gene, are now 
associated with roughly 20% of the fALS cases (Andersen et al. 2006; Bruijn et al. 2004; 
Valentine et al. 2005). Sporadic and familial ALS deteriorate the same neurons with similar 
pathology and cause progressive muscle weakness, spasticity, hyperreflexia, muscle atrophy, 
and paralysis. 
Although the causes of motor neuron death in ALS are poorly understood, a prominent 
hypothesis for SOD1-linked familial ALS involves the formation of protein aggregates 
containing misfolded hSOD1 as the main component in amyloid-like deposits. These 
components have been widely found both in the spinal cords of ALS patients (Jonsson et al 
2004; Shibata et al. 1996) and in transgenic mice developing ALS (Bruijn et al. 1997; 
Johnston et al. 2000; Wang et al. 2002; Watanabe et al. 2001). The precursors of these protein 
aggregates are believed to be soluble oligomeric intermediates of the hSOD1 aggregation 
process. These oligomers are thought to be responsible for gain of toxic function, similar to 
what has been proposed for other neurodegenerative diseases (Mulligan & Chakrabartty 2013; 
Ross & Poirier 2004). Althought mechanism regard to cytotoxicity of SOD1 aggregates is not 
fully clear, various hypotheses include mitochondrial dysfunction (Hervias et al. 2006), 
impairment of axonal transport, oxidative stress, perturbations in Ca
2+
 homeostasis and 
glutamate excitotoxicity (Tortarolo et al. 2006). 
However it is still an open question, whether the protein aggregates are the primary 
cause of ALS or a consequence and represent a defensive response aimed at protecting cells 
from the more toxic oligomeric species (Polymenidou & Cleveland, 2011). 
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1.2 Amyloid beta (Aβ) peptides 
Amyloid beta (Aβ) peptides are a group of 37 to 43 amino acids peptides that are 
derived from the intramembranous proteolytic cleavage of the amyloid precursor protein 
(APP) (Haass & Selkoe, 2007). APP is a member of an evolutionarily conserved gene family 
with two mammalian homologs, amyloid precursor-like proteins (APLP) 1 and 2 (Wasco et 
al. 1992, 1993). These proteins contain highly similar sequences in their ectodomains and 
intracellular carboxy-termini, but the transmembrane region comprising the Aβ peptide is 
unique to APP (Bayer et al. 1999). Although its primary physiological function remains 
unclear, APP has been implicated in a variety of processes such as intracellular signalling, 
synapse adhesion, trophic support, axon remodelling and apoptosis (Zheng & Koo, 2011). 
APP is processed via two major pathways that utilize different enzymes and result in 
distinct cleavage products (fig. 2). The non-amyloidogenic pathway precludes the formation 
of Aβ due to constitutive α-secretase-mediated cleavage in the middle of the Aβ domain (Esch 
et al. 1990). Alpha-cleavage of APP occurs mainly at the plasma membrane, releasing a 
soluble α-APP fragment (sAPPα) into the lumen/extracellular space and creating a membrane-
bound, 83-residue C-terminal fragment (C83) (Sisodia, 1992). The presence of sAPPα is 
associated with normal synaptic signalling and results in synaptic plasticity, learning and 
memory, emotional behaviors and neuronal survival. Subsequent intramembranous cleavage 
of C83 by γ-secretase liberates a soluble, 3 kDa fragment (p3) and the APP intracellular 
domain (AICD) (Zheng & Koo, 2011). The p3 fragment is rapidly degraded, while the AICD 
may act as a transcriptional regulator. 
The amyloidogenic processing of APP primarily occurs in the endocytic pathway. β-
secretase initiates the sequence of amyloidogenic cleavage events. Cleavage of APP at the β-
site generates a soluble amino-terminal fragment (sAPPβ) and a membrane-associated, 99-
residue C-terminal fragment (C99). γ-secretase then performs a stepwise, intramembrane 
cleavage of the C99 fragment, releasing various isoforms of Aβ and the AICD. The most 
common Aβ isoforms are Aβ40, a 40 residues peptide, and Aβ42 which contains an extra 
isoleucine and alanine residues on the C-terminus. Aβ40 form is the more common of the two 
- under physiological conditions, the ratio of Aβ42 to Aβ40 is about 1:9, but Aβ42 has more 
hydrophobic nature, and thus its aggregative ability and neurotoxicity are much greater than 
those of Aβ40 (Jan et al. 2010; Walsh et al. 2009). Both of these forms (Aβ40 and Aβ42) are 
targets of intense study.  
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Figure 2. APP metabolism by the secretase enzymes. Adapted from (Barrantes et al. 2010). 
 
1.2.1 Aβ polymorphism 
Aβ is a heterogeneous mixture of peptides which exist in a complex equilibrium, 
sensitive to numerous external factors. Under distinct conditions Aβ molecules can 
spontaneously self-aggregate in vitro into different species, which are having different 
solubility, stability and biological and toxic properties (Jan et al. 2010) (fig. 3). Aβ peptides 
can form soluble oligomers and protofibrils, which could be intermediates of a fibrillation 
process (Benilova et al. 2012). Recent studies have revealed the high neurotoxicity of these 
species and their close links with AD, showing e.g. that soluble Aβ oligomers extracted from 
Alzheimer's disease brains potently impair synapse structure and function (Benilova et al. 
2012; Chimon et al. 2007; Hoshi et al. 2003; Krafft & Klein, 2010; Kirkitadze et al. 2002; 
Lambert et al. 1998; Lesne´ et al. 2006; Noguchi et al. 2009; Selkoe, 2008; Shankar et 
al. 2008). Instead, the formation of amyloidal deposits consisting of Aβ fibrils is a 
pathological hallmark of AD. Although mature amyloid fibrils are sometimes described as 
being predominantly neutral (Aksenov et al. 1996), there is evidence in some recent reports 
that Aβ fibrils are also neurotoxic and that the progression of AD symptoms is correlated with 
the amount of these insoluble Aβ assemblies (Chimon et al. 2007; Lorenzo et al. 1994; 
Meyer-Luehmannet al. 2008; Petkova et al. 2005; Qiang et al. 2012; Selkoe et al. 2004; Walsh 
et al. 1999). In brain tissue, Aβ fibrils may initiate inflammation (Cameron & Landreth, 
2010; Glass et al., 2010) or oxidative damage (Sultana et al., 2009; Tougu et al., 2011). 
Additionally fibrillar oligomers (which may be fibril fragments), but not non-fibrillar 
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oligomers, have been reported to be elevated in AD patients (Tomic et al. 2009), that 
highlights likely causative role of Aβ fibrils in AD. On the other hand, it is commonly 
reported that asymptomatic elderly people develop amyloid plaques, while only about 30% of 
octagenerians develop AD, suggesting that amyloid fibrils alone might not destroy neurons 
(Tycko, 2011). Therefore the identity of Aβ aggregates that contribute most to neurotoxicity 
and neurodegeneration in AD and their pathogenic mechanisms is still a subject of 
controversy. 
Besides the different types of aggregates, the morphology of the same type of Aβ 
assemblies can also vary significantly depending on different aggregation conditions. This 
phenomenon is called polymorphism and has also been found in samples derived from AD 
patient brain tissues (Paravastu et al. 2009; Lu et al. 2013). Tissue from two Alzheimer’s 
disease (AD) patients contained a single predominant 40-residue Aβ (Aβ40) fibril structure in 
each patient, but the structures in the two patients were different. A molecular structural 
model developed for Aβ40 fibrils from one patient reveals features that distinguish in 
vivo from in vitro fibrils (Lu et al. 2013). Furthermore, it has been shown that different 
structures of Aβ fibrils can cause changes in neurotoxicity, which clearly highlights that 
polymorphism, revealed as structural variations, is extremely pathological relevant (Petkova 
et al. 2005). 
  
 
Figure 3. A putative schematic of aggregation of Aβ with two kinetic phases. In the lag phase 
monomers slowly form oligomers (dashed lines). In the elongation phase oligomers via 
protofibrils promote fibril formation (straight line). Adapted from (Kumar et al. 2011). 
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1.2.2 Overview of polymorphism and structural models of amyloidal fibrils 
Mature amyloid fibrils, the terminal stage of the fibrillogenic pathway, largely exhibit 
polymorphism, which is demonstrated in variations in shapes at mesoscopic scale, as well as 
at the microscopic and supramolecular level. The polymorphism of Aβ fibrils was determined 
in vitro by numerous different structural studies. Cryo-electron microscopy (cryo-EM) 
(Fändrich et al. 2011; Meinhardt et al. 2009), and solid-state nuclear magnetic resonance 
(SSNMR) (Benzinger et al. 1998; Bertini et al. 2011a; Lansbury et al. 1995; Paravastu et al. 
2008; Petkova et al. 2002, 2005, 2006; Qiang et al. 2011) in particular, revealed a large 
spectrum of Aβ40 fibrils polymorphisms, with molecular structures that depend on 
aggregation conditions. Aβ40 amyloid fibrils have been widely investigated and several 
structural models have recently been proposed using SSNMR (Bertini et al. 2011a, Paravastu 
et al. 2008; Petkova et al. 2002, 2006). A structural model of Aβ42 fibrils was proposed based 
on solution NMR and mutagenesis (Lührs et al. 2005). 
In all these fibrillar assemblies Aβ molecules are densely packed in extended β-sheets 
(ladders), but exhibit polydispersed morphology and differ from one another in lengths and 
bundle widths. Mature fibrils possess a long, straight and highly regular morphology and are 
characterized by a specific filamentous structure and usually contain 2–6 protofilaments that 
are more than 1 μm long and 8–12 nm in diameter. They display a cross-β X-ray fiber 
diffraction pattern as well as stainability with Congo red, resulting in green birefringence and 
exhibit positive Thioflavin-T binding response (Merz et al. 1983; Petkova et al. 2005; Serpell, 
2000). It is widely accepted that amyloid fibrils are insoluble deposits, but recent studies have 
shown that many biochemical factors, e.g. biological lipids, are able to efficiently revert the 
fibrillation process and convert these insoluble assemblies into soluble, highly toxic 
intermediate species (Martins et al. 2008). 
Experiment-based, several different Aβ40 and Aβ42 fibrils models demonstrate that 
the distinct polymorphism of fibrillar assemblies is reflected in variations in the overall 
structural symmetry (twofold vs. threefold), differences in specific aspects of structural 
elements, conformations and various residue sites, as well as in the nature of β-sheet 
structures including topologies of the β1-turn-β2 motif and inter-protofilament contacts 
(Ahmed et al. 2010; Bertini et al. 2011a; Lührs et al. 2005; Paravastu et al. 2008; Petkova et 
al. 2006) (fig. 4). All this models suggest that the Aβ molecule adopts a U-shaped 
protofilament structure, which hydrogen-bonds with identical molecules to form a pair of 
inregister, parallel β-sheets. However, the models differ in the precise location of the U-turn 
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in the sequence, as well as in the specific interactions between distal regions. The inter-β-
strand contacts within the U-shaped β-strand-turn-β-strand motif might be shifted in each 
fibril models, demonstrating that polymorphism is present at the protofilament level (Colletier 
et al. 2011). Recent studies have also shown that, in Aβ fibrils carrying mutants, both parallel 
and anti-parallel registry can occur (Qiang et al. 2011). Although the structural polymorphism 
of Aβ40 fibrils was initially described as taking place mainly at the supramolecular level 
(Paravastu et al. 2008), a recent structural model of mature Aβ fibrils (Bertini et al. 2011a) 
suggests that polymorphism can already originate at the level of the N-terminal conformation. 
The N-terminal part of the peptide in the fibril model can adopt βN-strand, but there is also 
evidence in the literature that a disordered conformation on the N-terminal part in some other 
Aβ fibrils is also possible (Paravastu et al. 2008; Petkova et al. 2006; Sachse et al. 2008, 
2010). Therefore the N-terminal part of Aβ40 peptides can adopt distinct conformations and 
thereby also contribute to structural diversity. 
It is reasonable to speculate that the folding of the monomer, the coexistence of 
multiple nucleation processes (each leading to a different fibril structure), and supramolecular 
packing (within and among protofilaments) are linked or even define the different 
morphology of amyloid fibrils through structural duplication/propagation along the fibril axis 
similar to the growth of 1D nanomaterials (Bertini et al. 2011a). Polymorphism of Aβ fibrils 
formation might be also attributed to the comparably high thermodynamic stabilities of 
distinct polymorphs, and the low rates of dissociation of peptide monomers or soluble species 
from fibrils (Qiang et al. 2013). Finally it is worth to mention that such multiplicity of Aβ 
species is derived not only from native biological variation, but also from the different 
techniques used to generate such species in vitro or to isolate them from brain tissue. The 
predominant discrepancies in morphology in Aβ40 fibril samples can be result of changes in 
growth conditions, specifically the presence or absence of gentle agitation of the peptide 
solution during fibril formation. Quiescent growth leads to fibrils with the morphology of 
“twisted pairs” (Paravastu et al. 2008), instead gentle agitation results in striated ribbons 
(Petkova et al. 2006) (fig. 5). The overall symmetry with which cross-β units are arranged is 
the difference between them. The “twisted pair” protofilament contains three cross-β units, 
related by an approximate three-fold rotational symmetry axis, whereas the “striated ribbon” 
protofilament contains two cross-β units, related by an approximate two-fold rotational 
symmetry axis that coincides with the long axis of the protofilament. Difference is also 
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observable in the conformation of 23-29 residues and sidechain-sidechain contacts between 
cross-β units (Tycko, 2011). 
 
 
Figure 4. Different topologies of β1-turn-β2 motif (left column) and inter-protofilament 
contacts (right column) in various SSNMR-derived structural models of Aβ fibrils ((a)Bertini 
et al. 2011a ; (b) Petkova et al. 2002; (c) Petkova et al. 2006; Paravastu et al. 2008; (d) Ahmed 
et al. 2010)). Adapted from (Bertini et al. 2011a). 
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Figure 5. Molecural structural model for a) striated-ribbon and b) twisted pair Aβ40 fibrils. 
Adapted from (Tycko 2011).  
 
1.2.3 Intermediate amyloidal species 
Intermediates amyloidal species e.g. oligomers, protofibrils, Aβ-derived diffusible 
ligands (ADDLs), as well as Aβ annular assemblies are likely involved in amyloid fibril 
formation. Various studies had reported that the neurotoxicity of Aβ peptides might be 
ascribed to these pre-fibrillar assemblies (Benilova et al. 2012; Chimon et al. 2007; Hoshi et 
al.2003; Kirkitadze et al, 2002; Krafft and Klein, 2010; Lambert et al. 1998; Lesne´ et al. 
2006; Noguchi et al. 2009; Selkoe, 2008) as a consequence of their structural flexibility and 
their hydrophobic exposure. Therefore the high-resolution structural characterization of these 
soluble species has become an overarching objective for understanding Aβ aggregation 
pathways, and complex molecular mechanism of AD (Benilova et al. 2012). 
Several in vitro SSNMR studies established an initial high-resolution insight into 
certain non-fibrillar (Ahmed et al. 2010; Chimon et al. 2005, 2007; Lopez del Amo et al. 
2012) and protofibrillar (Qiang et al. 2012; Scheidt et al. 2011) Aβ aggregates. Several other 
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experimental and theoretical methods have also been used to obtain residue-specific 
information on prefibrillar Aβ aggregates and on structural persistence in the monomeric state 
(Bernstein et al. 2009; Bertini et al. 2013b; Danielsson et al. 2006; Fändrich et al. 2012; Fawzi 
et al. 2011; Gallion 2012; Haupt et al. 2012; Kheterpal et al. 2006; Pan et al. 2011). 
Oligomers and protofibrillar intermediates are likely to be on a pathway to amyloid 
fibril formation. They might potently impair synapse structure and function, disturb 
neurotransmission and can cause cell death in vitro and in vivo. Their biological potency 
however depend on different polymorphic states. Protofibrils are structurally closest to the 
mature fibrils and might represent late-stage of the fibrillogenic pathway. They can be 
distinguished from oligomers by their elongated, linear shape, whereas oligomers are 
frequently referred as spherical species (fig. 6). Protofibrils usually adapt smooth, curvilinear 
structures and are thinner (diameters of usually less than 10 nm) and shorter (length usually 
below 400 nm) comparing to the fibrils. Instead oligomers contain a wide range of species, 
ranging from low molecular weight (LMW) (comprise dimers, trimers and tetramers) to high 
molecular weight (HMW) (including spherical, chain-like and annular structure) (Fändrich, 
2012; Benilova et al. 2012; Jan et al 2010). All of these intermediate assemblies are rich in β-
sheet structure and bind Congo red and Thioflavin-T, although more weakly than mature 
fibrils (Jan et al. 2010). 
  
Figure 6. Structure of oligomers, protofibrils and mature fibrils Aβ40. Adapted from 
(Fändrich, 2012). 
However, an investigation of these prefibrillar deposits faces many obstacles. As they 
are often thermally unstable compared to mature fibrils, in recent years many different 
methods to immobilize and study these species have been developed and each strategy has its 
own advantages and disadvantages. 
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Pioneering work in this direction has been performed by the groups of Smith and Ishii 
(Ahmed et al. 2010; Chimon et al. 2005, 2007), who focused on Aβ oligomeric form. Taking 
advantage of the fact that various proteins including Aβ retain their structures after 
lyophilisation (Benzinger et al. 1998; Petkova et al. 2002; Studelska et al. 1997), many groups 
trap the thermally labile intermediate by freeze-trapping and subsequent lyophilisation. 
Different methods of trapping oligomeric and protofibrillar Aβ species as: filtration through 
low molecular weight cut off filters (Bitan et al. 2005), photo-induced crosslinking of 
unmodified proteins (Bitan et al. 2003), organic solvent (Haupt et al. 2012), density gradient 
centrifugation (Ward et al. 2000), size exclusion chromatography (SEC) (Bitan et al. 2003; 
Hartley et al. 1999; Jan et al. 2010; Walsh et al. 1997) or interaction partners (Bieschke et al. 
2012; Lopez del Amo et al. 2012; Scheidt et al. 2011) were used.  
In this work we applied a novel method defined as sedimented solutes NMR 
(SedNMR) to detailed structural characterization of prefibrillar and fibrillar assemblies 
(Bertini et al. 2013b). In this method, solid-state NMR (SSNMR) experiments are used to 
observe proteins that are sedimented from solution using an ultracentrifugal field (Bertini et 
al. 2011b; 2012a; 2012b; 2013a; Polenova, 2011; Ravera et al. 2013). The application of 
SSNMR is possible, as it has been reported (Ahmed et al. 2010; Bernstein et al. 2009; Fawzi 
et al. 2011; Kirkitadze et al. 2002; Lee et al. 2011) that Aβ peptides in aqueous solutions 
spontaneously form soluble aggregates of high molecular weight (50–200 kDa) that are large 
enough to sediment and thus become visible by SSNMR. 
The sedimentation of macromolecules into this type of solid-like phase can be 
achieved in two different ways. Sedimentation through ultracentrifugation, either by magic 
angle spinning (in situ) or preparative ultracentrifugation (ex situ), can be used to immobilize 
and characterize oligomeric species, measure their formation kinetics, selectively sediment 
some of these species by their different molecular weights, and reveal the atomic-level 
structural features of soluble Aβ assemblies. 
The collective data obtained from all of these methods demonstrate probable pathway 
from these fibril precursors to terminal fibrillar states, and also provide evidence that these 
prefibrillar assemblies already contain β-strand structures (especially most hydrophobic 
regions), but with different supramolecular organizations and reduced structural order and 
periodic symmetry, which might define the structures of the multiple conformers in fibrils in 
amyloid misfolding. However, some authors have suggested that certain oligomers that do not 
further aggregate to amyloid fibers and that have different secondary structures exist among 
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the various Aβ intermediate species. Therefore the precise mechanism of the aggregation is 
still a matter of dispute. 
1.2.4 The importance of Aβ40: Aβ42 different ratio for promoting toxicity-associated β-
aggregation  
Aside from the fact that the neurotoxicity can be induced by the presence of either 
intermediate assemblies or mature fibrils, recent studies point out the relative ratio of Aβ40 
versus Aβ42 as an important determinant of Aβ aggregation, fibrillogenesis, and toxicity. Aβ 
peptides in specific compositions that balance hydrophilic and hydrophobic interactions might 
promote the formation of toxic β-aggregates and affect aggregation kinetics (Kuperstein et al. 
2010; Pauwels et al. 2012; Yoshiike et al. 2003; Jan et al. 2008). However, the molecular 
mechanisms by which changes in relative ratio induced and accelerated β-aggregation, fibril 
formation, and cellular toxicity remain uncertain. 
Aβ42 and Aβ40 alloforms co-exist in a molar ratio of 1:9 under normal physiological 
conditions in the brain. In patients with familial AD this ratio is shifted to a higher level of 
Aβ42 corresponding to a ratio of 3:7. Investigations of the properties of the Aβ40/Aβ42 
mixture by different groups has clearly shown that these two species interact and change each 
other’s dynamic behaviour (Yoshiike et al. 2003; Jan et al. 2008; Kim et al. 2007; Wang et al. 
2006). Even minor alterations in the relative amount of the Aβ42/Aβ40 ratio dramatically 
affect the biophysical and biological properties of the Aβ mixtures reflected in their 
aggregation kinetics by altering the pattern of oligomer formation. It has been shown that 
Aβ40 delays Aβ42 aggregation, while Aβ42 has an opposite effect and induces Aβ40 
aggregation. This observation was also confirmed by in vivo studies, which have shown that a 
higher percentage of Aβ40 peptides in the brain might be protective (Kim et al. 2007; Wang 
et al. 2006). 
Although it is generally assumed that alterations in the ratios of the Aβ40 and Aβ42 
mixture can stabilize distinct intermediate species associated with toxicity, the possibility that  
neurotoxicity is induced by a number of different conformations should not be neglected. This 
possibility can be explained by the fact that those toxic intermediate deposits might exist in 
dynamic equilibrium through theirs assembly and disassembly. 
Due to the fact that neurotoxic conformation(s) might be induced by particular ratio of 
Aβ40 to Aβ42, we focused on the mixture of the fibrils. In this work we will report throught 
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collective data obtained through SSNMR that a change in the AβM42:AβM40 ratio induces 
differences in conformational plasticity of the peptide mixtures. The main challenge of this 
project however is the identification of AβM40:AβM42 reciprocal association in the fibrils, 
that should broaden our understanding of exacts structural properties, as well as interaction 
and behavior of these components. 
 
1.3 Superoxide dismutase protein (hSOD1) 
Superoxide dismutase 1 (SOD1) is ubiquitously expressed in human cells where it 
mainly localizes in the cytosol and in the mitochondria intermembrane space (IMS) at 
micromolar concentrations (Okado-Matsumoto & Fridovich, 2011; Sturtz et al. 2001). At 
lower levels has been also found in the nucleus and in the peroxisomes. Functionally hSOD1 
is responsible for protecting cells from oxidative damage by eliminating superoxide ions 
through disproportionation (Bertini et al. 1998; Fridovich, 1978).  
 
1.3.1 hSOD1 structural characterization 
hSOD1 is a 32 kDa, β-rich, homodimeric protein. Each of the two subunits of SOD1 
forms an eight β-stranded Greek key β-barrel and contains several loops (fig. 6), as well as a 
catalytic copper ion (binding residues: His46, His48, His63 and His120) and a structural zinc 
ion (binding residues: His63, His71, His80 and Asp83). The protein is stabilized by an 
intrasubunit disulfide bond formed by Cys-57 and Cys-146 near the active site. In addition 
there are other two reduced Cys residues, Cys-6 and Cys-111, which are located on β-strand 1 
and loop VI respectively (fig. 7). Among the loops connecting the 8 β-strands, 2 have 
structural and functional roles. The electrostatic loop, namely loop VII (residues 121–144) 
contains charged residues and plays a role in attraction between negatively-charged 
superoxide substrate and positive site with copper ion. The long zinc loop, namely IV 
(residues 49–84) forms the zinc-binding site and is involved in interactions between the two 
subunits (Banci et al. 2007, 2008, 2009; Chattopadhyay et al. 2008; Fujiwara et al. 2007; 
Seetharaman et al. 2009; Shaw & Valentine, 2007). 
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Figure 7. Secondary structural elements of human SOD1 monomer. Adapted from (Shaw  & 
Valentine, 2007). 
 
1.3.2 hSOD1 misfolding and aggregation 
The unusually high stability for mature hSOD1, which retains enzymatic activity at 
high temperatures and in the presence of denaturing agents is ascribed most of all to the 
presence of metal ions (zinc and copper), dimerization, and an intramolecular disulfide bond. 
These posttranslational modifications are essential in the maturation of hSOD1. The lack of 
one or more of these features has a major impact on the properties of hSOD1 and may have 
relevance in hSOD1 acquisition of toxic properties (Lelie et al. 2011). 
Complete removal of the metal ions in hSOD1 could plays a crucial role in aberrant 
SOD1 oligomerization and aggregation (Teilum, 2009). Proteomic studies indicate that 
demetallated SOD1 protein is the main and constant component in amyloid deposits widely 
found in ALS patients and transgenic mice (Lelie et al. 2011), whereas in vitro studies of the 
aggregation kinetics have implicated the monomeric apo state as the origin for aggregation 
(Teilum, 2009). 
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These early species of the maturation process lacking metal ions have been shown to 
have high tendency to oligomerize in vitro, while the mature form of hSOD1 is not prone to 
aggregation (Banci et al. 2007; Furukawa et al. 2008;  Lindberg et al. 2002; Oztug Durer et al. 
2009). Previous studies have shown that lack of the metal ions causes dynamic motions and 
loosen up of the long active-site loops, contributing to the lower stability of the loop 
conformation, the stability of the β – barrel and whole protein scaffold (Danielsson et al. 
2011). Apo hSOD1 acquire high flexibility and can adopt a broad range of conformations, 
which are highly disordered in some parts and some of which cause the two free cysteines 
(Cys-6 and Cys-111) to be more exposed, solvent accessible, and less structurally constrained 
than in the metallated form. Once the free cysteines are solvent-accessible, form 
intermolecular disulfide bonds which cross-link the molecules into high-molecular-weight 
oligomers under physiological conditions (37°C, pH 7, and 100 µM protein concentration), 
which are further stabilized by noncovalent protein–protein interactions between β-sheets 
(Banci et al. 2007; 2009). These oligomers of high molecular weight (over MDa) are 
remarkably stable, persisting in the soluble state for months and exhibit positive ThT binding 
response (Banci et al. 2007; 2009).  
Although the stabilizing effects of metal ion binding have been known as significant 
factor contributing to dimer stability, recent studies have also emphasized the importance of 
the intrasubunit disulfide bond formed by Cys-57 and Cys-146. Intact disulfide bond shifts 
monomer-dimer equilibrium towards dimeric species (Arnesano et  al. 2004), which is further 
stabilized by reciprocal interactions of the loop IV and β-strand 8 across the molecular two-
fold axis. Reduction of the disulfide bond in the apo protein causes monomerization, as a 
result of strong destabilization of apo SOD1 scaffold by increase mobility of the disorder loop 
IV, partial destabilization of the β barrel and weakened interactions across the dimer interface. 
This could lead to partial misfolding and SOD1 aggregation processes (Chattopadhyay et al. 
2008; Seetharaman et al. 2009, Shaw & Valentine, 2007). 
Various studies demonstrated that hSOD1 local structural and dynamical properties, as 
well as the rate of the aggregation process are also changed in different way by diverse 
mutations. Hitherto, more than 100 ALS-linked mutants on hSOD1 have been found. The 
presence of a mutation and its location and type might contribute to acquirement by the 
protein the high flexibility through exposing areas prone to oligomerization, the abolishment 
of metal binding sites, the reduction of the surface charge, destabilize the dimer and loops 
(Shaw & Valentine 2007). 
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These discrepancy in the structural changes caused by disruptions in maturation steps 
of SOD1 as well as different ALS-linked mutants on hSOD1 resulting in divergence in the 
structural properties made it very difficult to understand the mechanism of hSOD1 misfolding 
and aggregation. However it is hypothesized that misfolded hSOD1 monomers might be the 
intermediate of further aggregation, leading at the final stage to amyloid deposits widely 
found in ALS patients and transgenic mice. 
 
1.3.3 Aggregation preventing strategy in hSOD1 
 
Many studies have been focused on the searching of therapeutic strategies aimed to 
prevent SOD1 pathogenic aggregation process that could be relevant with respect to the ALS 
pathology. Since SOD1 monomers are suspected to be the aggregation intermediates (Rakhit 
et al. 2004; Khare et al. 2004), these efforts concentrate on the stabilization of SOD1 dimers 
by the development of small, drug-like molecules. The mechanism of action of these 
molecules is based on the targeting directly free cysteine residues, which are solvent 
accessible. These molecules effect in neutralization of the free cysteines, which take part in 
the formation of intermolecular disulfide bonds, important in SOD1 amyloid formation. 
A recent study has shown that cis-diamminedichloroplatinum (II) (cisplatinum) can be 
selected as potential leading compound for blocking hSOD1 oxidative oligomerization (Banci 
et al. 2012). Cisplatinum is a small chemotherapeutic drug molecule with very high binding 
affinity toward thiol groups in proteins (Wang & Lippard, 2005). It has been proved that 
cisplatinum inhibits the oligomerisation of hSOD1 in vitro and in vivo by covalently binding 
to the solvent exposed Cys-111 of the apo-form of the enzyme and leads also to the 
dissociation of already formed apo hSOD1 oligomers without affecting the normal hSOD1 
enzymatic activity (Banci et al. 2012). This effect is relatively specific, since another cysteine 
reactive, anti-cancer molecule (Imexon) has no significant effect in the inhibition of SOD1 
oligomerization, probably because of its larger molecular size. Nevertheless clinical use of 
this chemotherapeutic agent is severely limited by the development of side effects including 
nephrotoxicity, emetogenesis, ototoxicity and neurotoxicity (Kelland 2007; Wang &Lippard 
2005). The peripheral neuropathy associated with these neurotoxic effects can be prolonged, 
severe and very often responsible for therapy interruption. Recent data have suggested that 
cisplatin also induces the formation of reactive oxygen species (ROS) that can trigger cell 
death (Brozovic et al. 2010; Casaress et al. 2012; Marullo et al. 2013). 
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It is thus clear that the availability of safe and effective analgesic drugs, able 
additionally to reverse or counterbalanced the toxic effects of cisplatinum related to the 
formation of ROS is a target of high interest. In this work we will report that such presumed 
candidates in suppression of cisplatinum-induced neuropathy are two molecules ADM_09 and 
ADM_12. 
1.4 Aims and topics of the study  
The aim of this work was the expression, purification as well as the structural and 
biophysical characterization of proteins involved in physiological and pathological processes 
at intra and extracellular level that play a role in a diverse group of neurodegenerative 
disorders. The first is beta amyloid peptide (Aβ), that is associated to Alzheimer’s disease 
(AD) and the second is superoxide dismutase (SOD1) that is related to amyotrophic lateral 
sclerosis (ALS). Both Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) are 
classified as proteopathies and characterized by progressive nervous system dysfunction and 
so far are relentless and incurable.  
Although the direct involvement of Aβ peptides in AD is well-documented, the toxic 
Aβ species and the precise mechanism of its neurotoxicity remain unclear. Moreover, there is 
still a significant gap between site-specific structural information and the complex structural 
diversity of Aβ amyloids. A detailed structural and functional characterization of fibrillar 
assemblies, as well as the various prefibrillar intermediates is crucial for understanding the 
role of Aβ formation and aggregation in AD pathogenesis. The recognition of the real culprit 
for AD onset is fundamental in design of new, effective therapeutic strategies targeted at 
preventing the formation or impairing the activity of toxic Aβ assemblies involved in AD. In 
this work a detailed structural characterization of prefibrillar and fibrillar Aβ assemblies has 
been carried out in order to elucidate the Aβ aggregation pathways, in particular, the structural 
evolution in different steps, and to identify the toxic Aβ species. We focused on high 
resolution structural characterization of AβM40 and AβM42 mixture fibrils prepared in 
different molar ration related to the pathological conditions and demontrated the application 
of a novel method defined as sedimented solutes NMR (SedNMR) to detailed structural 
characterization of oligomeric and prefibrillar assemblies. I contributed to the molecular, 
biological and biophysical part of the project, by preparing double/triple labeled or unlabeled 
protein samples by heterologous expression of various Aβ peptides in Escherichia coli and 
purification process. I performed fibrillation experiments under different conditions, as well 
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as prepared samples for isolation and characterization of Aβ oligomers and protofibrils that 
facilitated the combined solid state and solution NMR investigation. 
The causes of motor neuron death in ALS are poorly understood, however a prominent 
hypothesis for SOD1-linked familial ALS involves the formation of protein aggregates 
containing misfolded hSOD1 as the main component in amyloid-like deposits. Therefore 
many studies have been focused on the investigation of the therapeutic strategies aimed to 
prevent SOD1 pathogenic aggregation that could be relevant with respect to the ALS 
pathology. One of the rational drug design was established based on previous knowledge on 
the chemical mechanism of apo SOD1 aggregation and the chemical reactivity of cisplatin 
that selectively binds to solvent exposed Cys-111 and strongly inhibits process of 
oligomerization. However clinical use of this chemotherapeutic agent is severely limited by 
the development of neurotoxicity and others undesirable effects. Therefor the main objectives 
of this work was the determination of the propensity of two new molecules, ADM_09 and 
ADM_12 to revert side effects caused by cisplatinum related to the formation of ROS and 
cisplatinum-induced neuropathy pain. I contributed to the project by expression, purification 
of hSOD1 wt protein, preparation of the apo form of SOD1 and monitoring of SOD1 
aggregation by ThT fluorescence measurements. 
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Chapter 2   Methodology 
In this section the experimental procedures, methods and key materials are described.  
2.1 Recombinant protein expression in E. coli  
The requirement of rapid and economical production of high quality recombinant 
proteins, has driven the development of a variety of strategies for achieving high level 
expression of protein. These strategies involve several aspects such as expression vectors 
design, gene dosage, promoter strength, mRNA stability, translation initiation and 
termination, host design considerations, codon usage, and fermentation factors. The proper 
selection and manipulation of the expression conditions is essential in obtaining the high yield 
of protein at low cost (Jana & Deb, 2005). 
Several host systems for protein production, including bacteria, yeast, plants, fungi, 
insect and mammalian cells have been developed and evaluated (Shatzman 1995). Their 
choice depends on many factors, including cell growth characteristics, expression levels, 
intracellular and extracellular expression, posttranslational modifications as well as biological 
activity of the protein of interest. Extensive knowledge on the genetics and molecular biology 
of E. coli, made this expression system one of the most valuable for the high-level production 
of recombinant proteins. The important advantages of this host system is that the production 
of isotope labeled protein for NMR is less complex compared to other organisms. However 
not every gene can be expressed efficiently in this organism. This limitation may be due to the 
unique and subtle structural features of the gene sequence, degradation of the protein by host 
cell proteases, the ease of protein folding, as well as the potential toxicity of the protein to the 
host. Another drawbacks of E. coli as an expression system include the inability to perform 
many of the posttranslational modifications found in eukaryotic proteins, since E. coli is a 
prokaryote and lacks intracellular organelles, such as the endoplasmic reticulum and the Golgi 
apparatus, which are responsible for such processes. Moreover E. coli is lacking of a secretion 
mechanism for the efficient release of protein into the culture medium, and has the limited 
ability to facilitate extensive disulfide bond formation (Jana & Deb, 2005). 
Once the expression system is selected, the expression conditions should be tested. It 
is important to take into consideration such factors as culture media composition, temperature, 
optical density, isopropyl β-D-1-thiogalactopyranoside (IPTG) inducer concentrations, 
induction time, as well as different E. coli strain possessing various properties that could be 
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advantageous in the expression of the certain protein. Common examples are Rosetta(DE3) 
and Codon Plus for genes containing rare codons; Origami(DE3) for proteins containing 
disulfide bridges, Gold(DE3) for increasing expression yields and BL21(DE3)pLysS, which 
has a gene for lysozyme. Optical density has significant effects on both the cells and protein 
production. High cell-density culture systems suffer from several drawbacks, including 
limited availability of dissolved oxygen at high cell density, carbon dioxide levels which can 
decrease growth rates and stimulate acetate formation, reduction in the mixing efficiency of 
the culture, and heat generation. Nutrient composition and fermentation variables such as 
temperature, pH, and other parameters can differentially affect the translation of different 
mRNAs proteolytic activity, secretion, and production levels (Jana & Deb, 2005). The 
composition of the cell growth medium must be carefully formulated dependence of the 
expression purpose. The cells can be grown in different types of media: rich media, LB, 
2xYT, terrific broth, NZY and the minimum media M9. When the labelled protein is 
necessary, the M9 supplemented with [C
13
] and [N
15
] sources is used. In order to increase the 
expression yield of isotopic labeled protein the good solution is Marley method (Marley et al. 
2001). The cells transformed with the expression plasmid are grown initially in rich medium 
until high optical densities, then are centrifuged and exchanged into an isotopically defined 
minimal media enriched with (
15
NH4)2SO4(1 g/L) and (
13
C) glucose (4 g/L). There are also 
commercially available and isotopically enriched rich media e.g. Silantes., which are 
particularly advantageous for the expression of deuterated labeled protein in terms of 
simplified cells adaptation process.  
The best approach to verify simultaneously all these parameters is preliminary test 
expression performed in a small – volume scale. This tactic allows for the rapid identification 
of the optimal conditions to be reproduced in scale up downstream process of a soluble 
recombinant protein. Sometimes, however main fraction of the protein is produced in the 
insoluble fraction, as inclusion bodies. Although inclusion bodies are usually unwanted, cause 
of the problem with the refolding of the protein, they are good alternative in the case of 
intrinsically disordered proteins, as their separation from the cell lysate is easy and efficient 
way of protein purification. In case of ordered proteins this limitation can be overcome by 
refolding process. Nevertheless it is a challenging task, cause of the fact that each protein is 
unique and require specific approach for the refolding process. When all the refolding trails 
are unsuccessful, the last choices are to redesign the expressed domain or to use another 
expression system. 
35 
 
2.2 Protein purification 
High protein purity is essential for the characterization of the function, structure and 
interactions of the protein of interest. The number of applied purification steps will always 
depend upon the purity requirements and purpose for which the protein is needed. However, 
the best protein purification strategy is one in which the highest level of purification is 
reached in the fewest steps, since each protein purification step usually results in some degree 
of product loss. 
The preliminary step in protein purification is cell lysis, where the cells are disrupted 
and relevant protein fraction is extracted. The method of choice of protein extraction depends 
on how fragile the protein is and how sturdy the cells are. Its suitable selection is crucial, 
because inadequate chosen method can affect the target protein’s integrity and activity, or 
expose it to degradative conditions. Among many various mechanical, physical or chemical 
techniques, more frequently used are sonication, repeated freeze-thaw lysis, detergent lysis, 
enzymatic lysis and osmotic lysis. The extraction process also release proteolytic enzymes 
which might degrade or artificially modify the extracted protein, that lower the overall yield. 
To prevent these effects it is usually desirable to add directly in the cell suspension a cocktail 
of protease inhibitors, proceed quickly, and keep the extract cooled, to slow down proteolysis.  
The subsequent steps of purification procedure involve several chromatographic 
methods. Their choice depends mainly on the biophysical and biochemical properties of 
specific protein and exploit differences in protein size, charge, as well as binding affinity. 
Among many different chromatography techniques, the three most used techniques in this 
work were: ion exchange chromatography (IEX), size exclusion chromatography (SEC) and 
immobilized metal ion affinity chromatography (IMAC). 
Ion exchange chromatography (IEX) separates proteins with differences in charge. The 
separation is based on the reversible interaction between a charged protein and an oppositely 
charged chromatographic medium. The sample is loaded onto a column in conditions favoring 
specific binding, such as calibrated pH and low ionic strength salt concentration, in order to 
enhance the interaction between target protein and column matrix. The net surface charge of a 
protein varies according to the surrounding pH. Typically, when the pH is above its isoelectric 
point (pI), a protein will bind to a positively charged anion exchanger. Below its pI, a protein 
will bind to a negatively charged cation exchanger. Elution is usually performed by changing 
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the pH or the ionic strength of the elution buffer in a gradient, or stepwise. Most commonly, 
samples are eluted with salt (NaCl), using a gradient elution. 
Size-exclusion chromatography (SEC) is a chromatographic technique in which 
molecules are separated by their size, ideal for the final step purification for the preparation 
high purity samples. The column matrix is composed of a range of beads with slightly 
different pore sizes. When the dissolved molecules of various sizes flow into the column, 
large molecules migrate quickly through the column, because they do not penetrate the pores. 
On the other hand, small molecules enter deep into the pores and consequently flow more 
slowly through the column. SEC can be used to separate protein by size and shape, to 
exchange the buffer and isolate protein mixtures, as well as separate monomers from 
aggregates. High resolution fractionation can be used to determine the molecular mass 
performing a molecular weight distribution analysis using available standards.  
Immobilized metal ion affinity chromatography (IMAC) is the most used affinity 
technique in case of peptide with fusion tags. IMAC separates proteins on the basis of 
reversible interaction between side-chains of specific amino acids (usually histidine) and a 
specific ligand attached to a chromatographic matrix (mainly chelated transition metal ions 
e.g. Zn
2+ 
or Ni
2+
). The target protein is usually washed from the impurities and then, eluted 
using increasing concentration of imidazole, which acts like a competitive agent. Desorption 
might be also performed nonspecifically by changing pH, which decrease the affinity of the 
tag for the resin, changing ionic strength or polarity. To remove the fusion partner from the 
target protein, enzymatic digestion using a specific protease such as TEV, Thrombin etc. is 
necessary. In order to separate the fusion tag from the target native protein a second IMAC is 
usually performed. 
2.3 Biotechnological production of Aβ peptides. 
I described the biotechnological methods of samples preparation of different kinds of 
Aβ peptides. 
The AβM40, Iowa (D24N) and Flemish (A22G) mutants of AβM40 and AβM42 
peptides without any fusion tags, as well as Aβ40 and Aβ42 without starting methionine fused 
with N-terminal hexahistidine affinity tag, were expressed as inclusion bodies in E. coli.  
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2.3.1 Aβ peptides with Met  
The complementary DNA of AβM40/AβM42 was cloned in the pET3a vector using 
the NdeI and BamHI restriction enzymes. 
 In order to obtain Iowa (D24N) and Flemish (A22G) mutants of AβM40, site directed 
mutagenesis was performed. 
The peptides were expressed in the BL21 (DE3)pLys  E. coli strain. The expressed 
peptides contain exogenous N-terminal methionine due to the translation of start codon. 
However, as it is reported in the literature (Walsh et al. 2009), the presence of an N-terminal 
methionine, does not affect the fibrillation kinetics or morphology of the fibrils formed by 
AβM40 or AβM42. In order to increase the proteins yield, the growth was performed using 
the Marley method (Marley et al., 2001). The cells transformed with the AβM40/AβM42 
expression plasmid were predominately grown in rich medium at 37°C until OD600 reached 
0,6, centrifuged and exchanged into an isotopically defined minimal media enriched with 
(
15
NH4)2SO4(1 g/L) and [
13
C] glucose (4 g/L). The peptides expression was induced with 1.2 
mM isopropyl β-D-1-thiogalactopyranoside and cells were harvested after 4 hours incubation 
at 39°C. 
The peptides were purified as reported (Bertini et al. 2011a; Hellstrand et al. 2010; Jan 
et al. 2010; Walsh et al. 2009) with some modifications using a combination of anion-
exchange and size exclusion chromatography. All the manipulations were performed at 
slightly alkaline pH in order to avoid the formation of structural contaminants produced by 
isoelectric precipitation. The inclusion bodies were first solubilized with 8M urea and then 
purified by ion exchange chromatography performed in batch. The use of free resin in the 
batch mode versus prepacked column (DEAE-cellulose column) prevent the possible 
aggregation and allows to obtain high yield of monomeric peptide (Walsh et al. 2009). For 
this purpose resin DE52 on Büchner funnel with filter paper on a vacuum glass bottle was 
used. Elution was done using different concentration of buffer of NaCl. Protein was eluted 
with 125 mM concentration of the salt. In the case of AβM42, protein was also presented in 
fraction 20 mM, 150 mM, 200 mM and 1M, probably cause of progressive aggregation of the 
sample. Guanidinium chloride was then added to the solution to reach the final concentration 
of 6 M. All obtained fraction of diluted protein was concentrated to final volume using 
Amicon device. A number of methods to concentrate the Aβ solution was examined. 
Although several different methods, within the 3 kDa molecular mass cut-off centrifugal 
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devices, proved useful, Amicon device resulted as the best solution for highly concentrated 
proteins. The next step of purification was gel filtration, which was performed using the 
preparative column Sephadex 75 HiLoad 26/60 with the 50 mM (NH4)OAc pH 8.5 as a 
buffer. The obtained fractions were collected together and concentrated. During all 
purification protein purity was analysed using SDS-PAGE electrophoresis, whereas the 
protein concentration was estimated using spectrophotometer. 
This two-step purification allow to obtain a highly pure products with the yield in the 
range 10 mg of AβM40 and 5-10 mg AβM42 per liter of culture. 
2.3.2 Aβ peptides without Met 
Aβ40 and Aβ42 was produced in the E. coli cytoplasm as fusion protein with N-
terminal hexahistidine affinity tag. The fusion construct consists of a soluble polypeptide 
segment comprising 19 repeats of the tetrapeptide sequence NANP, a TEV protease cleavage 
site (sequence ENLYFQ), dipeptide linker sequences and the Aβ sequence. 
Aβ40 and Aβ42 without methionine were expressed in the BL21 (DE3) E. coli strain. 
Cells were grown in rich medium (LB or Terrific broth) till high OD values. The peptide 
expression was induced with 1-1.2mM IPTG and cells were harvested after 4 hours 
incubation at 39°C. After the removal of the soluble proteins the inclusion bodies were 
solubilized with 20mM TRIS pH 8.0, 8M and purified by affinity chromatography using a 
nickel chelating (His-Trap) column under the denaturating conditions, followed by digestion 
with AcTEV protease. To avoid protein aggregation and improve the separation of 
cutted/uncutted protein 8M urea or 6M guanidine hydrochloride was introduced in second 
affinity column steps. As a final step of purification a gel filtration in 50mM ammonium 
acetate pH 8.5 using a Sephadex 75 26/60 column was used. Obtained protein was dialyzed in 
water and liofilized.  
In order to improve the tag digestion in case of Aβ42 peptides, different purification 
procedure, introducing organic solvents were adopted. The inclusion bodies were solubilized 
by 6M guanidinium chloride, and the protein was purified by metal chelating affinity 
chromatography on Ni
2+
-nitrilotriacetic acid agarose in the presence of 6M guanidinium 
chloride lowering the pH. The fusion proteins were further purified via reversed phase high-
performance liquid chromatography (RP-HPLC) using semi-preparative Zorbax SB300 C8 
column (Agilent), lyophilized from aqueous acetonitrile and directly used for TEV protease 
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cleavage. A cleavage efficiency of about 70% was achieved after incubation at pH 8.0 and 
4°C for 16 h at a protein concentration of 100 μM in the presence of 5 μM TEV protease. The 
cleavage mixture was subsequently applied to RP-HPLC which allowed quantitative 
separation of the hydrophobic Aβ42 peptide from the other, more hydrophilic components in 
the cleavage reaction. The final yield of purified Aβ42 was 20 mg/l of culture.  However this 
approach encounter problem with solubilization of liofilized protein in water. To disaggregate 
the Aβ and generate monomeric random coil structure different procedures were proposed: 
predissolution of the peptide in dilute base solution, predissolution in TFA and 1,1,1,3,3,3-
hexafluoro-2-propanol solvents (HFIP) (Jao et al. 1997). Finally already reported protocol 
(Broersen et al. 2011) for the solubilization of Aβ peptide, that involves sequential 
solubilization using structure-breaking organic solvents hexafluoroisopropanol and DMSO 
followed by column purification and results in standardized aggregate-free Aβ peptide was 
applied. As it was reported in pure DMSO, Aβ appears to be monomeric and lacks any β -
sheet character (Shen and Murphy 1995). 
2.4 Preparation of Aβ fibrils for solid state NMR (SSNMR) studies 
A general overview 
Highly ordered and homogeneous samples is crucial for high-resolution studies by 
SSNMR. However, in amyloid systems it is rather common that several differently shaped 
aggregates coexist in a mixture, making preparation of the proper samples very difficult. They 
usually increase the complexity of spectra and impede further data analysis at site-specific 
level. These limitations can be overcome by programmed isotopic labelling schemes or 
sequence truncation, but each of these methods hampers complete structural analysis by 
SSNMR. Another strategy to overcome this restraint is the seeding procedure, which leads not 
only to an improvement in the homogeneity of Aβ fibrils, but also permits insights into the 
molecular structures of amyloid fibrils developing in human tissue. This tactic is feasible after 
reconstruction of isotope enriched in vivo fibrils using brain tissues as seeds from patients 
with AD (Paravastu et al. 2009). This approach is made possible by the fact that in vitro 
studies have shown that seeding procedure allows for obtaining fibrils that retain exactly the 
same molecular structures, corresponding to the seeds from the brain of patients with AD 
(Petkova et al. 2005). This strategy also has many drawbacks, because the sample obtained in 
this way might contain significant contamination from many tissue components such as lipids. 
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However it permits to restore pathological samples from AD patients and get high resolution 
structural characterization of these assemblies. 
As heterogeneity also depends significantly upon different aggregation conditions, 
several different factors must be taken into consideration. One important key factor is the 
purity of the starting materials. The presence of pre-existing aggregates can result in a lack of 
reproducibility, as well as in a meaningful discrepancy in fibrillogenesis kinetics. Several 
different protocols have been developed in order to solve this issue, resulting in standardized 
aggregate-free Aβ peptide samples (Broersen et al. 2011, Jao et al. 1997, Fezoui et al. 2000). 
Disaggregation of the Aβ assemblies involved the use of the structure-breaking organic 
solvents hexafluoroisopropanol (HFIP) and DMSO, trifluoroacetic acid (TFA) pre-treatment, 
and pre-dissolution of the peptide in a dilute base solution (e.g. NaOH). Aggregates might be 
also removed by less drastic methods as filtration, using a syringe filter (0,20 μM) or 
centrifugation. Each of these approaches allows aggregate-free material to be obtained. 
Another significant aspect is represented by the conditions of the fibrillation protocols such as 
concentration, pH, ionic strength, temperatures. The incubation of the sample in quiescent 
condition leads to fibrils with the morphology of “twisted pairs” (Paravastu et al. 2008), 
instead gentle agitation results in striated ribbons (Petkova et al. 2006) or “flat” striated 
bundles (Bertini et al. 2011a). The appropriate selection of fibrillation strategy is essential for 
obtaining high quality samples for high resolution SSNMR. 
Protocol for generation of Aβ fibrils 
In this work, fibril mixture samples of double labeled AβM40 and unlabeled AβM42 
in molar ratio (7:3), double labeled AβM40 and unlabeled AβM42 in molar ratio (1:1) and 
double labeled AβM42 and unlabeled AβM40 in the molar ratio of (1:1) were prepared. 
Samples of Aβ fibrils for the SSNMR studies were prepared according to previously 
published, validated and optimized protocol (Bertini et al. 2011a), which provides the high 
reproducibility of the samples. Uniformly (
13
C,
15
N) – enriched protein samples at 100 μM 
concentration in 50 mM ammonium acetate (pH 8.5) were filtered through a 0,20 μM syringe 
filter and subsequently incubated at 37 °C under shaking (950 rpm) for 4 weeks. Fibrils were 
collected by the overnight ultracentrifugation at 60000 rpm (ca. 2.65 × 105 g) and 4 °C for 24 
h. The pellet was washed with fresh and cold ultrapure water (Millipore) for three times (1 
mL per time), and then wet material was packed into a 3.2 mm ZrO2 MAS rotor under 4 °C. 
The fibril samples were kept fully hydrated during all the steps. 
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2.5 Biotechnological production of hSOD1 apo protein 
 
I described the method of samples preparation of wild type (wt) superoxide dismutase 
(SOD1) protein and its mutant C57A/C146A for spectroscopic characterization. 
 
Superoxide dismutase (SOD1) wild type (wt) and SOD mutant C57A/C146A were 
overexpressed in the BL21 DE3 Origami plys E. coli strain. The fusion proteins were 
obtained by growing the cells in minimal medium in shaking flasks at 37°C until OD600 
reached 1 and then induced with 0.5 mM IPTG for 12 h at 25°C. Proteins were isolated by 
sonication in 5 mM imidazole buffer at pH 8 and centrifuged at 40 000 RPM for 20 min. 
Purification was performed by affinity chromatography using a nickel chelating (His-Trap) 
column and digestion with AcTEV protease. Next step of purification was gel filtration, 
which was performed using the preparative column Sephadex 75 HiLoad 26/60. The metal-
free proteins was prepared by the dialysis according to previously published protocols 
(McCord & Fridovich, 1969). 
2.6 Biophysical characterization 
Biophysical techniques provide low-resolution structural characterization of biological 
macromolecules. However they require small amounts of biological material, and what is 
more important they don’t demand labeling, what make them excellent complementation of 
NMR study. 
2.6.1 UV-visible spectroscpy (UV-vis) 
UV-visible spectroscopy (UV-vis) is a technique that measure the absorption of 
electromagnetic radiation by molecules in the ultrviolet-visible region. In this region of the 
electromagnetic spectrum, molecules undergo electronic transition.  
UV-vis spectroscopy allows for following ligand-binding interactions, enzyme 
catalysis, conformation transitions and is commonly used as a tool to quantify the 
concentration of proteins and nucleic acids. Potein concentration can be determined by the 
absorption around 280 nm (most of the proteins contain aromatic acid residues - tryptophan, 
tyrosine and phenylalanine), using the protein extinction coefficient and the Beer-Lambert 
law. 
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2.6.2 Fluorescence spectroscopy 
Fluorescence spectroscopy is a common technique used in studies of the structure and 
dynamics of macromolecules, which allows a real-time observation of the dynamics of intact 
biological systems with an unprecedented resolution. In fluorescence spectroscopy, the 
molecule is first excited, by absorbing a photon, from its ground electronic state to one of the 
various vibrational states in the excited electronic state. This higher energy state is unstable, 
and when the molecule returns to the ground state again a photon with a different wavelength 
is emitted and can be measure (Lakowicz 1983). 
Fluorescent studies provide a number of information about physical and 
physicochemical properties of proteins, as well as theirs intermolecular interactions and 
conformational changes. In addition, fluorescence spectroscopy can be used to study those 
structural and dynamic properties of proteins which are directly related to such biological 
functions as specific binding (recognition), biocatalysis, membrane transport, and muscular 
motility. 
However, the use of fluorescence spectroscopy is only possible when the biologically 
active compounds contain in their structure a fluorophore. Fluorescent proteins contain three 
aromatic amino acid residues (tryptophan, tyrosine, phenylalanine) which may contribute to 
their intrinsic fluorescence when are excited by ultraviolet light. The most important is the 
presence of tryptophan, which has much stronger fluorescence and higher quantum yield than 
the other two aromatic amino acids.  
In this work fluorescence spectroscopy was used to monitor the formation of 
oligomeric species by hSOD1 wt in the presence of cisplatinum and in the presence of 
cisplatinum together with small molecules (MNO1106 and MNO1109) according to 
previously described procedure (Banci et al. 2007 ; Banci et al. 2008). The solution 
fluorescence emission was measured, over time of incubation, with a Cary 50 Eclipse 
spectrophotometer supplied with a single-cell Peltier thermostated cell holder regulated at 
37˚C. Fluorescence was followed with ThT, a dye that binds to extended β-sheets, which is 
typical structural feature of amyloids (Biancalana & Shohei 2010; Naiki et al.1989). Free ThT 
has excitation and emission maxima at 350 and 450 nm, respectively. However, upon binding 
to amyloid-oligomers, the excitation and emission wavelengths change to 450 and 485 nm, 
respectively. Fifty-four microliter aliquots of sample were added to 646 µl of a 215 µM Tht 
solution in a 20 mM phosphate buffer at pH 7.0. The background fluorescence spectrum of 
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the buffer was subtracted. The excitation wavelength was 446 nm (bandwidth, 10nm), and the 
emission was recorded at 480 nm (bandwidth, 10 nm). Fluorescence intensity at 483 nm was 
plotted against the time of incubation. 
2.6.3 Transmission electron spectroscopy (TEM) 
Transmission electron microscopy (TEM) is a microscopy technique in which a beam 
of electrons is transmitted through an ultra-thin specimen of interest, interacting with the 
specimen as it passes through. An image is formed from the interaction of the electrons 
transmitted through the specimen. Once the electrons pass the anode, they are focused by 
condenser lens onto the sample grid. The sample grid is usually a copper mesh grid with a 
support film. Before TEM analysis, specimen of interest is adsorbed to this film and typically 
stained using a heavy metal salt which have high atomic number capable of scattering 
electrons. 
The TEM reveals levels of detail and complexity inaccessible by light microscopy, 
because it uses a focused beam of high energy electrons and allows detailed micro-structural 
examination through high-resolution. It is used to investigate the morphology, examine the 
structure, composition, and properties of specimens in submicron detail. 
 Here transmission electron microscope was used to characterized the morphology and 
molecular architecture of Aβ fibrils and prefibrillar aggregates. For TEM tests, a solution of 
Aβ fibrils was dropped and dried on a Cu grid covered by carbon film. The fibrils were then 
stained in freshly prepared aqueous uranyl acetate solution for 20 min. After that the grid was 
rinsed gently using ultrapure water for 1 min and dried again. The bright-field TEM images 
were collected on a Philips CM12 microscope operating at 80 kV. 
2.7 SSNMR spectroscopy 
 
NMR spectroscopy is a technique based on the interaction of the nuclear spin with the 
electromagnetic radiation, in the presence of an external magnetic field. Nowadyas solution 
and solid state NMR (SSNMR) are powerful tools to characterize the structure, dynamics, and 
interactions of biomolecules. Solution NMR is the most common tool for structure 
determination, but SSNMR is becoming important technique as a consequence of 
developments in sample preparation and in theoretical background.  
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SSNMR is one of the best techniques for obtaining atomic resolution structures of 
amyloid fribrils sufficient for the development of complete molecular models (Tycko 2010). 
Since application of X-ray crystallography is limited to small amyloidogenic peptides and 
cryo-electron microscopy (cryo-EM) is hindered by its relatively low spatial resolution, 
SSNMR allows for substantial advancement in understanding the structure of amyloid fibrils. 
In this work SSNMR was applied to detailed structural characterization of prefibrillar 
and fibrillar assemblies. To investigate prefibrillar deposits a method termed sedimented 
solutes NMR (SedNMR) was used. To immobilize macromolecules and make them amenable 
for SedNMR studies, sedimentation through ultracentrifugation, either by magic angle 
spinning (in situ) (Bertini et al. 2011b) or preparative ultracentrifuge (ex situ) (Bertini et al. 
2012) was introduced. In situ SedNMR allows to control the kinetics of formation of soluble 
Aβ assemblies. Ex situ sedimentation by common ultracentrifuge with the help of devices 
previously designed to pack NMR rotors with precipitates or microcrystals (Böckmann et al. 
2009) effectively increase the amount of solid-state NMR sensitive material in the rotor 
improving this way the sensitivity of the experiments. This approach allows for sedimentation 
of even smaller solutes and allows to obtain species of different molecular weights by 
changing the experimental conditions. 
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Chapter 3   Results 
 
3.1 Formation kinetics and structural features of Beta-amyloid aggregates by 
sedimented solute NMR 
I performed protein expression, purification and electrophoresis tests together with Gianluca 
Gallo and supported preparation the ultracentrifugation samples for SSNMR. I participated in 
data analysis and interpretation, and wrote with Gianluca Gallo part of matherials and 
methods for the manuscript and contribuited in paper revision. 
 
3.2 Structural characterization of AβM40/AβM42 fibril mixture 
I contributed to the molecular, biological and biophysical part of the project, performing 
expression, purification and fibrillation experiments (including optimization) together with 
Gianluca Gallo. I participated in data analysis and interpretation, as well as in writing of the 
draft. 
 
3.3 Lipoic derivatives in synergistic treatment of human superoxide dismutase with 
cisplatin  
I expressed and purified hSOD1 wt protein and prepared apo form of SOD1. I also carried out 
monitoring SOD1 aggregation by ThT fluorescence measurements and wrote part of the draft. 
 
3.4 From IDP to Alzheimer’s disease. Brief review 
I proposed the content of the chapter, wrote together with Tatiana Kozyreva first draft and 
contributed in the chapter revision. 
 
3.5 Recombinant IDPs for NMR. Tips and tricks 
I contributed to the content of the chapter and participated in the chapter revision. 
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Introduction 
Amyloid β (Aβ) peptides have been widely considered responsible for the onset of the 
neurodegenerative process in the Alzheimer’s disease (AD) (Annaert and De Strooper 2002). 
One of the principal hallmark of AD are, indeed, amyloidic senile plaques, constituted by 
amyloid fibrils, formed from the aggregation process of Aβ peptides. Aβ peptides are 
generated from the amyloid precursor protein (APP) by β- and γ-secretases-combined 
cleavage, that produces a heterogeneous mixture of peptides varying in length at their 
carboxy-termini (from 37 to 43 amino acids). The two major Aβ species are constituted by 40 
and 42 amino acids, respectively. Although neurotoxicity can be induced by deposits of Aβ 
fibrils, recent studies have established close link between the reciprocal ratio of Aβ40 and 
Aβ42 and the stability of intermediate neurotoxic species. Moreover, Aβ40 and Aβ42 have 
been found to affect each other’s aggregation kinetics (Kuperstein et al 2010; Pauwels et al 
2012). According to these studies, neurotoxicity might be explained by the dynamic nature of 
the ongoing Aβ aggregation process, rather than by the prevailing view that Aβ toxicity is 
associated with a distinct assembly. A change in the Aβ42:Aβ40 ratio induces differences in 
the conformational plasticity of the oligomeric peptide mixtures and in the pattern of the 
detectable oligomeric species (Yoshiike et al 2003; Jan et al 2008a; Jan et al 2010; Kuperstein 
et al 2010; Pauwels et al 2012). Investigation of the properties of the mixture of Aβ40 and 
Aβ42, by different groups, clearly show that this two species interact, as well as one changes 
the dynamic behavior of the other. It was proved that Aβ40 delays Aβ42 aggregation, whereas 
Aβ42 has an opposite effect and induces Aβ40 aggregation. This observation was also 
confirmed by in vivo studies, which have showed that higher percentage of Aβ40 peptides in 
the brain might have a protective effect (Wang et al 2006; Kim et al 2007). 
Under normal physiological conditions in the brain, Aβ40 and Aβ42 alloforms co-exist 
in molar ratio 9:1. Conversely, in patients with familial AD this ratio is shifted to a higher 
level of Aβ42 and correspond to 7:3. At this point, a detailed structural characterization of 
Aβ40:Aβ42 mixed fibrils is needed. In the present paper, the structure of Aβ40:Aβ42 mixed 
fibrils in different molar ratios has been investigated, in order to shed light on the processes 
related to the onset of the disease and on their correlation with Aβ peptides reciprocal ratios. 
Mixed fibrils of AβM40 and AβM42 peptides in the molar ratios of (7:3) and (1:1) have been 
prepared and analyzed through transmission electron microscopy (TEM) and solid state NMR 
(ssNMR). The conformation acquired by the two peptides in the fibrils and their reciprocal 
organization along the fibril axis has been investigated. 
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Materials and Methods 
 
Expression, Purification, and sample preparation of Aβ40: Aβ42 mixed fibrils 
The cDNA of AβM40/AβM42 was cloned in the pET3a vector using the NdeI and BamHI 
restriction enzymes. The peptides were expressed in the BL21 (DE3)pLys E. coli strain. Both 
polypeptides contain an exogenous N-terminal methionine residue (Met0), due to the 
translation start codon, that has been shown not to play a significant role in aggregation, nor 
in toxicity, as reported in the literature (Walsh et al 2009). The growth of AβM40 and AβM42 
peptides was performed using the Marley method (Marley et al 2001). The cells transformed 
with the AβM40/AβM42 expression plasmid were predominately grown in rich medium at 
310 K until OD600 reached 0.6, centrifuged and exchanged into an isotopically defined 
minimal media enriched with (
15
NH4)2SO4 (1 g/L) and [
13
C] glucose (4 g/L). The peptide 
expression was induced with 1.2 mM IPTG and cells were harvested after 4 hours incubation 
at 312 K. The peptides were purified as reported in literature (Walsh et al 1999; Jan et al 
2008b; Walsh et al 2009; Hellstrand et al 2009; Bertini et al 2011) with some modifications 
using a combination of anion-exchange and size exclusion chromatography. All the 
manipulations were performed at slightly alkaline pH in order to avoid the formation of 
structural contaminants produced by isoelectric precipitation. The inclusion bodies were first 
solubilized with 8M urea and then purified by ion exchange chromatography performed in 
batch. For this purpose resin DE52 on Büchner funnel with filter paper on a vacuum glass 
bottle was used. Elution was done using different concentration of buffer of NaCl. The protein 
was eluted with 125 mM concentration of the salt. In the case of AβM42, the protein was also 
present in fraction 20 mM, 150 mM, 200 mM and 1M, probably because of progressive 
aggregation of the sample. All obtained fractions of diluted protein were concentrated to final 
volume using Amicon device. The next step of purification was gel filtration, which was 
performed using the preparative column Sephadex 75 HiLoad 26/60 with the 50 mM 
(NH4)OAc pH 8.5 as buffer. The obtained fractions were collected together and concentrated. 
During all the purification steps, the protein purity was analysed using SDS-PAGE 
electrophoresis, whereas the protein concentration was estimated using the spectrophotometer. 
These two-steps of purification allow to obtain highly pure products with the yield in the 
range of 10 mg for AβM40 and 5-10 mg for AβM42 per liter of culture. 
The mixed fibrils for ssNMR studies were produced according to the protocol 
described in Bertini et al. 2011. The samples were obtained by mixing batches of 
13
C, 
15
N-
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uniformly enriched AβM40 polypeptide with aliquots of the AβM42 polypeptide in natural 
isotopic abundance. The mixtures of 70µM AβM40 and 30µM AβM42 and of 50 µM AβM40 
and 50 µM AβM42 in 50 mM ammonium acetate (pH 8.5) were incubated at 310 K under 
shaking (950 rpm) for 5 weeks. Fibrils were collected by the overnight ultracentrifugation at 
60000 rpm and 277 K for 24 h. The pellet was washed with fresh and cold ultrapure water 
(Millipore) for three times (1 mL per time), and then ∼14 mg of the wet material were packed 
into a 3.2 mm ZrO2 magic angle spinning (MAS) rotor at 277 K. The fibril samples were kept 
fully hydrated during all steps. The mixture of 
13
C, 
15
N-uniformly enriched AβM42 
polypeptide and AβM40 polypeptide in natural isotopic abundance was prepared using the 
same protocol. 
 For transmission electron microscopy (TEM) tests, a suspension of Aβ40:Aβ42 mixed 
fibrils was dropped and dried on a Cu grid covered by carbon film. The fibrils were then 
stained in freshly prepared aqueous uranyl acetate solution for 20 min. After that, the grid was 
rinsed gently using ultrapure water for 1 min and dried again. Bright-field TEM images were 
collected on a Philips CM12 microscope operating at 80 kV. 
NMR measurements 
NCA, NCO, NCACX (3D), NCOCX (3D), NCACB (3D), N(CO)CACB(3D) and 
CANCO (3D) experiments were performed on a Bruker Avance III 850 MHz wide-bore 
spectrometer (20.0 T, 213.7 MHz 
13
C Larmor frequency) equipped with a 3.2 mm DVT MAS 
probe head in triple-resonance mode. The MAS frequency (ωr/2π) was 14.0 kHz (± 2 Hz) 
during most of these experiments. The NCA, NCO, NCACX (3D), NCOCX (3D), NCACB 
(3D), N(CO)CACB (3D) and CANCO (3D) experiments were carried out using the standard 
pulse sequences as reported in the literature.  
2D 
13
C-
13
C proton-driven spin diffusion (PDSD)/DARR correlation spectra and 2D 
13
C-
13
C SHANGHAI with different mixing times (15, 25, 50, 75, 100, 200, 300, 400, 800 ms) 
were recorded on a Bruker Avance 700 MHz wide-bore instrument (16.4 T, 176.0 MHz 
13
C 
Larmor frequency) equipped with a 3.2 mm DVT probe head in the double-resonance mode. 
During the 2D 
13
C-
13
C DARR mixing time, a radio frequency (RF) pulse of constant strength 
equal to ωr/2π was applied on the 1H channel. For these experiments, the MAS frequency was 
stabilized at 12 kHz (± 2 Hz). During the experiments carried out using the 3.2 mm probe 
heads, the sample was cooled by a dry, cold air flow (> 935 L/h) generated by a BCU unit 
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(BCUXtreme or BCU-05), and the effective sample temperature during the experiments was 
estimated to be ∼283 K. 
All spectra were processed with the Bruker TOPSPIN software packages and analyzed 
by the program CARA (Computer Aided Resonance Assignment, ETH Zurich) (Keller 2003). 
ssNMR data analysis and structural modeling. 
 The sequential assignment of the new species present in the AβM40:AβM42 mixed 
fibrils was performed starting from the identification of the unique 31Ile-32Ile couple and 
following the same procedure reported in Bertini et al. 2011. The secondary structural 
probability was calculated by the TALOS+ program using the chemical shifts of the N, C, Cα, 
Cβ atoms.  
For model building, the length of β1 and β2 strands was based on the secondary 
structure predicted by the TALOS+ program. The β1- and β2-strands were then docked to one 
another by the HADDOCK program (Dominguez et al 2003; de Vries et al 2010) using the 
experimental long-range β1-β2 restraints. HADDOCK calculations were performed on the 
WeNMR GRID (http://www.wenmr.eu/) through the HADDOCK webserver Guru interface. 
All observed long-range contacts were implemented in the calculation. The lower distance 
cutoff in the HADDOCK calculations was set to 3.0 Å, and the upper distance cutoff was set 
to 6.0 Å for the shorter mixing contacts (100 and 200 ms) and to 7.5-8.0 Å for the long 
mixing contacts (300 and 400 ms). The charges on the N- and C-termini of the β1-strands and 
on the N-termini of the β2-strands were not included in the calculations in order to prevent 
electrostatic interactions, which do not exist when the two β-strands are linked by a turn 
region. The histidine protonation states were automatically determined by the WHATIF 
program which is embedded in the HADDOCK server on the WeNMR GRID. During the 
rigid docking calculations, 1000 structures were generated, then the best 200 structures were 
selected for the semi-rigid simulated annealing in torsion angle space, and finally refined in 
Cartesian space with explicit solvent.  
The β-sheets were then constructed by duplicating the β1 and β2 strands along the 
direction of the backbone N-H and C=O bonds with PYMOL, using a typical inter-strand 
distance of 4.8 Å (Kirschner et al 1986), according to the parallel registry (see Results). Eight 
β-strands for each β1 and β2 sheets were built, considering for the β2-sheet an alternation of 
the Aβ40 and Aβ42 sequences. 
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The turn regions were randomly generated using the program MODELLER (Sali and 
Blundell 1993; Fiser and Šali 2003) and the final one was selected from the resulted pool of 
50 structures.  
Similar to the procedure used to define the monomer folding, the inter-protofilament 
structural model was calculated by docking two β2-sheets from two different protofilaments 
through the HADDOCK WeNMR GRID webserver. The Guru interface was used for job 
submission so that non-crystallographic symmetry restraints between the two β2-sheets could 
be defined in the calculation. All observed intermolecular long-range contacts and inter-strand 
distance restraints were implemented in the calculations. All the restraints were duplicated 
symmetrically between the two β2-sheets using the same protocol used for structural 
calculations of symmetric dimers. Since these long range distance restraints could be 
identified only using long mixing times, the upper distance cutoffs in the HADDOCK 
calculation was set to 8.0 Å. Semi-flexible refinement was enabled on both β2-sheets.  
Results and Discussion 
TEM Characterization, High-Resolution SSNMR Spectra, and Sequential Assignment. 
The mature fibrils of AβM40:AβM42 in the ratio of 7:3 were analyzed through 
Transmission Electron Microscopy (TEM) and Solid State NMR (SSNMR). TEM 
micrographs revealed that the morphology of the fibrils is consistent with the results 
previously presented by Kuperstein et al. 2010 and by Pauwels et al. 2012. TEM micrographs 
of the mixtures of these fibrils (Figure 1) showed that the sample is mainly composed by short 
(100 μm) and highly entangled fibrillar material. The average section across is about 8±1 x 
18±4 nm. The samples contain mainly “striated” bundles composed by laterally associated 
filaments, as it occurred for the previous sample of AβM40 alone. The morphology of 
“twisted pairs”, which were observed in the Aβ40 fibrils prepared under quiescent conditions, 
is not observed in our samples. 
 
75 
 
 
 
Figure 1. Transmission electron microscopy (TEM) micrographs of fibrils mixtures of double labeled AβM40 
and unlabeled AβM42 in molar ratio (7:3). 
 
Although TEM micrograph seems to suggest a large heterogeneity in the fibrils, the 
quality of the obtained SSNMR spectra is comparable with that of the spectra obtained from 
samples containing fibrils formed by the AβM40 polypeptide alone (Bertini et al 2011). 
Protein sample was analyzed through dipolar-coupling based 2D 
13
C-
13
C SHANGHAI 
spectra and 2D 
15
N-
13
C correlation spectra (NCA/NCO). 2D 
13
C-
13
C-SHANGHAI spectrum 
of the fibril mixtures was overlaid with to the 2D 
13
C-
13
C-DARR spectra of fibrils AβM40 
prepared in the same solution condition and 2D 
15
N-
13
C NCA spectrum of the fibril mixtures 
was overlaid with to the 2D 
15
N-
13C NCA spectra of fibrils AβM40 (Figure 2). The registered 
spectra resemble those of the fibrils formed by the AβM40 polypeptide alone, with several 
additional signals. This suggests the presence of two specie, one corresponding to the AβM40 
polypeptide with the same conformation and contacts previously characterized by Bertini et 
al. 2011, and a second species with a different conformation and/or contacts. The ratio 
between the two species has been estimated from 2D 
13
C-
13
C DARR and 2D 
13
C-
13
C  
SHANGHAI spectra to be of the order of 30%, not consistent with an asymmetric dimer as 
basic subunit (Lopez del Amo et al 2012). Another extremely important clue is provided by 
the fact that no cross-peaks between the two different forms of AβM40 can be observed. 
200 nm 
Length: 17.28 nm 
Length: 13.90 nm 
Length: 19.28 nm 
76 
 
a) b)  
Figure 2. a) 2D 
13
C-
13
C-SHANGHAI spectrum of the fibril mixtures in molar ratio 7:3 (green) overlaid with to 
the 2D 
13
C-
13
C-DARR spectra of fibrils AβM40 (red). Magnetic field: 700 MHz (16.4 T), dimension of rotor: 3.2 
mm (~14 mg of fibrils), 12 kHz spinning, 100 kHz 
1
H decoupling, b) 2D
 15
N-
13
C NCA spectrum of the fibril 
mixtures in molar ratio 7:3 (green) overlaid with to the 2D 
15
N-
13C NCA spectra of fibrils AβM40 (red). 
Magnetic field: 700 MHz (16.4 T), dimension of rotor: 3.2 mm (~14 mg of fibrils), 14 kHz spinning, 100 kHz 
1
H 
decoupling. 
 
However high resolution structural analysis of this sample by SSNMR was hampered 
due to its high heterogeneity. In order to shed light on the structural features of the mixed 
fibrils, a new samples of double labeled AβM40 and unlabeled AβM42 fibrils in a ratio 1:1 
were prepared. The figure below shows the comparison of the 2D NCA spectra of the 1:1 
AβM40:AβM42 mixture (green) with respect to the Aβ40 fibrils. The spectra obtained from 
the 1:1 mixed fibrils are simplified with respect to those of the 7:3 mixed fibrils, with only the 
cross-peaks corresponding to the new species detectable (Figure 3). 
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a) b)  
Figure 3. a) 
13
C-
13
C-SHANGHAI spectrum of the fibril mixtures in molar ratio 1:1  (green) overlaid with to the 
13
C-
13
C-DARR spectra of fibrils AβM40 (red). Magnetic field:700 MHz (16.4 T), dimension of rotor: 3.2 mm 
(~14 mg of fibrils), 12 kHz spinning, 100 kHz 
1
H decoupling, b)
 15
N-
13
C NCA spectrum of the fibril mixtures in 
molar ratio 1:1 (green) overlaid with to the 
15
N-
13C NCA spectra of fibrils AβM40 (red). Magnetic field: 700 
MHz (16.4 T), dimension of rotor: 3.2 mm (~14 mg of fibrils), 14 kHz spinning, 100 kHz 
1
H decoupling. 
 
In order to perform the full assignment of the resonances of the new species, a toolbox 
of SSNMR experiments (2D NCA, 2D NCO, 3D NCACX, 3D NCOCX, 3D CANCO, 3D 
NCACB and 3D N(CO)CACB) were acquired. The sequential assignment of the backbone 
and side-chains of AβM40 forming the new species was successfully obtained (fig. 4). 
 
Figure 4. 
15
N-
13
C NCA spectra of the fibril mixtures in molar ratio 1:1: the full assignment of the spectrum is 
displayed. 
The strategy used for the assignment is illustrated in (Figure 5).  
78 
 
 
Figure 5 . Assignment strategy used for the sample of AβM40:AβM42 (1:1) mixture. Four correlated strips 
(planes NCB) of the 3D spectra NCACB and N(CO)CACB are displayed. The combination of these 3D spectra, 
together with 3D NCOCX and NCACX, allowed for the sequential assignment of the AβM40. 
 
β-Strand-Turn-β-Strand Motif of Aβ40 in Aβ40:Aβ42 Protofilaments 
The secondary structures of AβM40 polypeptide, predicted by TALOS+, in the 
mixture of the fibrils, contains a β-strand-turn-β-strand motif as found in other Aβ40 fibrils, 
with N-terminal region showing some propensity to form β-strand (Figure 6).  
 
 
Figure 6. Secondary structure prediction of AβM42:AβM40 (1:1) fibrils obtained with Talos+. 
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The organization of the β-strand-turn-β-strand motif has been investigated in detail. 
Signals correlating the side chains of Leu17 with Leu34/Val36, Phe19 with Gly33/Leu34, and 
Ala21with Ile32 were detected and assigned unambiguously on the 
13
C-
13
C SHANGHAI 
spectra with 100-400 ms mixing times. These long-range unambiguous restraints are only 
consistent with the conformation of the U-shaped motif. The folding of the monomer, called 
also β –arch, was calculated with the same protocol reported in Bertini et al. 2011, using 
HADDOCK (Dominguez et al 2003; de Vries et al 2010). In the current conformation of the β 
–arch, as indicated by the contacts, a different reciprocal packing of the two beta-strands (β1 
and β2), with respect to the model obtained for the fibrils of AβM40 alone (Bertini et al. 
2011), is observed (Figure 7). The conformation assumed by AβM40 in the presence of 
AβM42 resemble the most that reported in literature for fibrils of AβM42 alone (Ahmed et al 
2010) with respect to that of fibrils of AβM40 alone (Bertini et al 2011). Interestingly, 
AβM42 seems to force AβM40 to assume its own conformation in order to better maximize 
the hydrophobic contacts and minimize the steric hindrance due to the addition of two further 
residues at the C-termini.  
 
Aβ40  
Current 
Model 
Aβ40  
Bertini et 
al. 2011 
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Figure 7. Folding of monomeric Aβ40 peptide a) in the model of Aβ42:Aβ40 (1:1) fibrils and b) in the model 
obtained for the fibrils of AβM40 alone (Bertini et al. 2011). The linker between β1 and β2 was generated using 
Modeller. 
This result further supports the idea that the polymorphism of Aβ40 fibrils is not only 
due to different inter-protofilaments lateral association, but can also derive from the structural 
differences in the β-strand-turn-β-strand motif, since these are the building blocks of the 
mature fibrils. 
The analysis of the cross-peaks in the various spectra (SHANGHAI, DARR/PDSD) 
supports a parallel packing of the protein molecules in the proto-filament. In particular, no 
cross peaks correlating the beginning and ending parts of β1 or β2 segments can be assigned 
in an unambiguous and consistent manner. Therefore, the β-strand-turn-β-strand motifs must 
be organized in parallel cross-β sheets as reported in literature for mature fibrils of Aβ40 
(Petkova et al 2002; Petkova et al 2006; Paravastu et al 2008; Ahmed et al 2010; Qiang et al 
2011; Bertini et al 2011). 
Moreover, the presence of a single pattern of signals for each residue in the ssNMR 
spectra only agrees, for symmetric considerations, with the presence of a parallel in-registry 
β-spine (Nielsen et al 2009).  
Inter-protofilament Interactions in Mature Aβ40:Aβ42 mixed fibrils. 
The lateral association among different proto-filaments in the fibrils has been also 
calculated implementing long-range distance restraints in HADDOCK. Contacts among the 
C-terminus and the N-terminus of β2-strand have been found from the ssNMR spectra 
analysis, indicating the presence of an head to tail antiparallel association of two β2-strands of 
different monomers. In particular, contacts between the side chains of Ile31 with Val39/Val40 
and Met35 with Gly38/Val39 have been assigned from 
13
C-
13
C SHANGHAI and 
DARR/PDSD spectra. These experimental restraints are in agreement with two-fold rotational 
symmetry (or a so-called co-aligned homo-zipper (Nielsen et al 2009)) and with the parallel 
registry of the protofilament.  
Folding of Aβ42 in Aβ40:Aβ42 mixed fibrils. 
A sample containing a mixture of double labeled (
13
C
15
N) AβM42 and unlabeled 
AβM40 in the molar ratio of (1:1) has been further prepared with the purpose to characterize 
the conformation of AβM42 in the fibrils.. 
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The spectra of AβM42 appear almost completely superimposable to those of AβM40, 
indicating that the conformations acquired by the two peptides are mostly the same (figure 8). 
The two C-terminal residues of AβM42 could be also identified and assigned in the NCA 
spectrum.  
 
 
 
 
 
a) b) 
 
 
Figure 8. a) 2D
 15
N-
13
C NCA spectrum of AβM42 13C:15N/AβM40 unlabelled (1:1) (blue) overlaid with to the 
2D 
15
N-
13
C NCA spectrum of AβM40 13C:15N/ AβM42 unlabelled (1:1) (red). Magnetic field: 700 MHz (16.4 T), 
dimension of rotor: 3.2 mm (~14 mg of fibrils), 12 kHz spinning, 100 kHz 
1
H decoupling, T = 265 K. b)  2D 
13
C-
13
C- DARR spectrum of AβM42 13C:15N/AβM40 unlabelled (1:1) (blue) overlaid with to the 2D 15N-13C 
NCA spectra of AβM40 13C:15N/ AβM42 unlabelled (1:1) (red). Mixing time = 100 ms. Magnetic field: 700 
MHz (16.4 T), dimension of rotor: 3.2 mm (~14 mg of fibrils), 12 kHz spinning, 100 kHz 
1
H decoupling, T = 
265K. 
 
Aβ40/Aβ42 reciprocal association in the mixed fibrils 
In order to identify AβM40:AβM42 reciprocal association in the fibrils, we took into 
account three different possible reciprocal packing of Aβ40 and Aβ42 peptides along the fibril 
axis (figure 9). The first one can be excluded since in this case we would have had separated 
fibrils of AβM40 and of AβM42, that mean that the conformation adopted by AβM40 in the 
mixed fibrils should be the same of that of AβM40 fibrils alone. Experimental data obtained 
through SSNMR demonstrate that it is not the case. The other two models are equally possible 
since the experimental distance restraints can support both of them. 
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Figure 9. Putative AβM42:AβM40 reciprocal association in fibrils mixture. Pink color correspond to AβM42 
and blue color correspond to AβM40 fibrils. The models were generated with HADDOCK and Modeller. 
 
New insight in the polymorphism of Aβ peptides and the related fibrils. 
The collective experimental data obtained through SSNMR and TEM demonstrate that 
a change in the AβM42:AβM40 reciprocal ratio induces a variation in the formed specie. 
From the registered spectra, we evaluated that the molar ratio 7:3 favor the presence of two 
specie, one corresponding to the AβM40 polypeptide with the same conformation and 
contacts previously characterized by Bertini et al. 2011, and a second species with a different 
conformation and/or contacts, whereas the molar ratio 1:1 facilitate the specific formation of 
only one species - aggregates of AβM40 and AβM42 together. The new conformation 
assumed by Aβ40 in the presence of Aβ42 reflects the dynamic behavior of these peptides. 
These results indicate that different relative ratios of Aβ peptides are responsible of the 
formation of different toxic specie correlated with the onset of the Alzheimer’s disease. 
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Lipoic derivatives in synergistic treatment of human superoxide dismutase with 
cisplatin. 
 
Human superoxide dismutase 1 (hSOD1) is strongly implicated in the onset of 
amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the 
progressive dysfunction and loss of motor neurons (Bruijn  et al. 2004; Valentine et al. 2005). 
The causes of motor neuron death are poorly understood, but a prominent hypothesis involves 
the formation of protein aggregates containing misfolded hSOD1 as the main component in 
amyloid-like deposits which have been widely found both in the spinal cords of ALS patients 
(Jonsson et al 2004; Shibata et al. 1996) and in transgenic mice developing ALS (Bruijn et al. 
1997; Johnston et al. 2000; Wang et al. 2002; Watanabe et al. 2001). The precursors of these 
protein aggregates are believed to be soluble oligomeric intermediates of the hSOD1 
aggregation process. These oligomers are thought to be responsible for the toxic gain of 
function, similar to what has been proposed for other neurodegenerative diseases (Mulligan & 
Chakrabartty 2013; Ross & Poirier 2004). 
hSOD1 is ubiquitously expressed in human cells where it mainly localizes in the 
cytosol and in the mitochondria intermembrane space (IMS) at micromolar concentrations 
(Okado-Matsumoto & Fridovich, 2011; Sturtz et al. 2001). At lower levels has been also 
found in the nucleus and in the peroxisomes.  
hSOD1 is a homodimeric metalloprotein harboring in each subunit, a catalytic copper 
ion and a structural zinc ion, an intrasubunit disulfide bond between a highly conserved pair 
of cysteine (Cys-57 and Cys-146) and two free cysteines (Cys-6 and Cys-111). Functionally 
hSOD1 is responsible for protecting cells from oxidative damage by eliminating superoxide 
ions through disproportionation (Bertini et al. 1998; Fridovich 1978). 
The early species of the maturation process (i.e. misfolded SOD1 lacking metal ions) have 
been shown to have high tendency to oligomerize in vitro, while the mature form of hSOD1 is 
not prone to aggregation (Banci et al. 2007; Furukawa et al. 2008;  Lindberg et al. 2002; 
Oztug Durer et al. 2009). Previous studies have shown that in the apo hSOD1 the two free 
cysteines (Cis-6 and Cys-111) become solvent accessible and form intermolecular disulfide 
bonds which cross-link the molecules into high-molecular-weight oligomers under 
physiological conditions (37°C, pH 7, and 100 µM protein concentration) (Banci et al. 2007; 
2009). These oligomers of high molecular weight (over MDa) are remarkably stable, 
persisting in the soluble state for months and exhibit positive Tht binding response (Banci et 
al. 2007; 2009). An experimental mutation at Cys-111 (C111S) inhibited the aggregation of 
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ALS-mutant SOD1s in human and mouse neuronal cell lines (Karch et al. 2008; Cozzolino et 
al. 2008). Moreover, mice expressing a metal deficient variant where all copper- and zinc-
binding histidine residues were mutated, together with Cys-111 and Cys-6 
(H43R/H46R/H48Q/H63G/H71R/H80R/H120G/C6G/C111S), did not develop pathologic 
symptoms of ALS on the contrary to the expected due to the lack of any metal binding 
(Prudencio et al. 2012). In addition, such variant was not found in detergent-insoluble 
fractions of either mouse spinal cords or cell models, suggesting that it has a low aggregation 
propensity. Since the mutant protein created by converting residues at position 6 and 111 back 
to cysteine exhibited a remarkably increased aggregation propensity (Sheng et al. 2012), the 
lack of aggregation propensity of the previously mentioned variant likely resulted from the 
absence of Cys-6 and Cys-111. These findings further confirm the important role of the two 
non-conserved cysteine residues in modulating SOD1 aggregation and in particular of Cys-
111. Cys- 111 is also critical for mutant SOD1 to associate with mitochondria and thus has 
been proposed to be a key mediator of mitochondrial dysfunction caused by aggregation of 
mutant SOD1 in the mitochondrial compartment (Ferri et al. 2006). 
A recent study has shown that cis-diamminedichloroplatinum (II) (cisplatinum) can be 
selected as potential leading compound for blocking hSOD1 oxidative oligomerization (Banci 
et al. 2012). Cisplatinum is a small chemotherapeutic drug molecule with very high binding 
affinity toward thiol groups in proteins (Wang & Lippard, 2005). It has been proved that 
cisplatinum inhibits the oligomerisation of hSOD1 in vitro and in vivo by covalently binding 
to the solvent exposed Cys-111 of the apo-form of the enzyme and leads also to the 
dissociation of already formed apo hSOD1 oligomers without affecting the normal hSOD1 
enzymatic activity (Banci et al. 2012). Nevertheless clinical use of this chemotherapeutic 
agent is severely limited by the development of side effects including nephrotoxicity, 
emetogenesis, ototoxicity and neurotoxicity (Kelland 2007; Wang & Lippard 2005). The 
peripheral neuropathy associated with these neurotoxic effects can be prolonged, severe and 
very often responsible for therapy interruption. Recent data have suggested that cisplatin also 
induces the formation of reactive oxygen species (ROS) that can trigger cell death (Brozovic 
et al. 2010; Casaress et al. 2012; Marullo et al. 2013).  
 It is thus clear that the availability of safe and effective analgesic drugs, able 
additionally to reverse or counterbalanced the toxic effects of cisplatinum related to the 
formation of ROS is a target of high interest. Such presumed candidates in suppression of 
neuropathic pain are two molecules ADM_09 and ADM_12 (Nativi et al. 2013). ADM_09 
and ADM_12 are structurally new compounds obtained from synthesis of commercially 
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available (±) α-lipoic acid with proved antioxidative and analgesic properties (Parcker et al. 
1995) and L-carnosine witch has been proven to scavenge reactive oxygen species (ROS) 
(Hipkiss, 2009), in which a synergic combination of features of theirs two substrates was 
coupled in order to enhance theirs antioxidative and analgesic properties. It has been proved 
by in vivo experiments that ADM_09 is able to effectively revert neuropathy pain induced by 
oxaliplatin (OXA) without eliciting the commonly observed negative side effects (Nativie et. 
al. 2013). In vitro tests clearly showed the absence of any toxic effect of this compound 
(Nativi et al. 2013). Patch-clamp recordings demonstrated that ADM_09 is an effective 
antagonist of the nociceptive sensor channel TRPA1 (Nativi et al. 2013). The TRPA1 channel 
is activated by several mechanisms and has been actively investigated as a target to control 
neuropathic pain (Karashima et al. 2009; Nilius et al. 2012). This channel has been reported to 
mediate in OXA-evoked allodynia (pain evoked by an innocuous stimulus) and neuropathic 
pain (NeP) in rats by activation likely caused by glutathione-sensitive molecules (Nassini et 
al. 2011). A chemical activation mechanism of TRPA1 as a nociceptive sensor involves the 
interaction of its cysteine residues (that constitute the nucleophilic sites of disulphide bond 
formation) with reactive compounds, which activate the nociceptive response and causes the 
opening of the channel. For ADM_09 it has been proposed a dual-binding mode of action, in 
which a synergic combination of calcium-mediated binding of the carnosine residue and 
disulphide-bridge-forming of the lipoic acid residue accounts for the observed persistent 
blocking activity toward the TRPA1 channel (Nativi et al. 2013).  
Current study was undertaken to determine the anti-oxidative propensity of two 
molecules, ADM_09 and ADM_12, as well as to establish the ability of these two molecules 
to revert side effects caused by cisplatinum. We found that these compounds do not change 
the biochemistry of cisplatin and its interaction with hSOD1. Oligomerization of hSOD1 wt in 
the presence of cisplatinum together with small molecules (ADM_09 and ADM_12) is still 
inhibited, what means that the molecules does not modify the behavior of cisplatin and do not 
disrupt cisplatin to bind SOD1. ADM_09 and ADM_12 are detectable antioxidative agents 
and might be remarkably effective in the treatment of cisplatinum-induced neuropathy. 
Results 
To investigate the properties of these molecules towards cisplatinum we incubated 
ADM_09 and ADM_12 (1 mM) under physiological conditions in the presence of the 0,8 mM 
cisplatin. Apo hSOD1 in the absence of cisplatinum shows a progressive enhancement of Tht 
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fluorescence signal, consistent with previous finding (Banci et al. 2007). Cisplatinum 
efficiently inhibits the oligomerization of SOD1 showing slower increase in intensity in Tht 
fluorescence over time, as already have been reported (Banci et al. 2012). Oligomerization of 
hSOD1 in the presence of cisplatinum together with small molecules (ADM_09 and 
ADM_12) is still inhibited, what means that the molecules do not modify the behavior of 
cisplatin and do not disrupt cisplatin to bind SOD1 (fig. 1).  
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Figure 1. Fluorescence due to ThT binding to hSOD1. Plot of intensity of fluorescence versus time (h) for 
oxidized form of apo hSOD1 WT incubated with small molecules:  ● hSOD1 control, ▲ hSOD1+cisPt 0,8mM, 
▼ hSOD1+ADM_12 1mM +cisPt 0.8 mM, ♦ hSOD1+ADM_09 1mM +cisPt 0.8 mM.  
 
Antioxidative properties. 
The antioxidant profile of ADM_09 and ADM_12 was evaluated in vitro by 
measuring the oxidation of nitro blue tetrazolium (NBT) after 30 min, in the absence and in 
the presence of an increasing concentration of ADM_09 and ADM_12 (Table 1). In the 
absence of small molecules, superoxide anion (O2
−
) generated by the hypoxanthine – xanthine 
oxidase system increased the oxidized NBT level from 100 (basal) to around 4000 A.U. 
While in  the presence of ADM_09 in the reaction mixture, the oxidation of NBT was 
inhibited in a concentration-dependent manner (Table 1). For example, 100 μM ADM_09 
decreased the oxidized NBT from 4000 to 3200 A.U., indicating a detectable antioxidative 
activity. However, comparing the efficacy of ADM_09 with other commonly employed 
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antioxidants, including lipoic acid, it is easily appreciated that its antioxidative properties are 
only moderate and, notably, markedly less effective than the parent lipoic acid (Nativi et al. 
2013). Apparently, coupling of lipoic acid with carnosine affected the antioxidative capability 
of the former residue, inducing a significant loss of acivity. 
The antioxidative properties of ADM_12 are much more potent. The presence of 
ADM_12 in the reaction mixture inhibits the oxidation of NBT and reveal the strong 
antioxidative activity of ADM_12, that is comparable to its parent substrate – lipoic acid. 
Control Oxidation 
ADM_09 
concentration (µM) 
  0.1 1 3 30 100 1000 
100 ± 15 
4069 ± 
184 
3842 ± 
180 
3753 ± 
138 
3764 ± 
141 
3704 ± 
118* 
3216 ± 
133** 
3159 ± 
65** 
 
Control Oxidation 
ADM_12 
concentration (µM) 
  0.1 1 3 30 100 1000 
100 ± 16 3996 ± 81 
3753 ± 
116 
3790 ± 70 
3629 ± 
56* 
3611 ± 
112* 
2844 ± 
42** 
109 ± 
37** 
 
Table 1. Evaluation of the antioxidative properties of ADM_09 and ADM_12 by the NBT assay. O2
-
 generated 
by hypoxanthine-xanthine oxidase reaction was used to oxidize NBT (Nitro Blue Tetrazolium). The oxidation 
kynetic was spectrophotometrically measured at 560 nm in the absence or in the presence of tested compounds. 
Values are expressed as absorbance arbitrary units (A.U.). Control was arbitrarily fixed at 100 A.U. *P<0.01 
with respect to the Oxidation value. 
The antioxidative properties of ADM_12 were also tested in vivo in rat cortical 
astrocytes. Because glial cells exert a pivotal role in the development of neuropatic pain, 
astrocytes from primary cultures were used in the antioxidative tests, as these are directly 
related to normal tissues. In primary cultures of astrocytes, the neurotoxic compound 
oxaliplatin (100 μM) induced a significant increase of  SOD-inhibitable superoxide anion 
after 4 h of incubation, as evaluated by the cytochrome C assay (Fig. 2). Co-incubation with 
100 μM ADM_12 inhibited the O2
−
 formation by over 50% with respect to the untreated 
culture. This test was performed towards oxaliplatin since this chemotherapeutics agent has 
similar neurotoxicity profiles to cisplatinum, however is has much more clinical use. 
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Figure 2. SOD – inhibitable superoxide anion levels in astrocyte cell lines. Astrocytes ( 5*105 cells/well, 3 
control wells and 2 wells pre-treated with ADM_12) were exposed to 100 μM OXA for 4h. The effect of 100 
μM ADM_12 co-incubation on SOD-inhibitable superoxide anion levels are depicted. The non specific 
absorbance measured in the presence of SOD was subtracted to the total value. Values are expressed as mean ± 
s. e. m. of 3 experiments. *P<0.01 vs control and ^P<0.01 vs OXA treatment.  
 
Overall, these data indicate that ADM_09 and ADM_12 in particular, possess 
antioxidative properties that may be beneficial for the cisplatinum – induced oxidative stress. 
We found that these compounds do not change the biochemistry of cisplatin and its 
interaction with hSOD1. Previously published data (Nativi et al. 2013), suggest that ADM_09 
and ADM_12 might be possible candidates in suppression of neuropathic pain induced also 
by cisplatinum. Antihyperalgesic properties of those compounds toward cisplatinum require 
confirmation by in vivo tests, which are in progress by now and are very promising. These 
findings might open a door toward a novel synergistic therapeutic strategies in amyotrophic 
lateral sclerosis (ALS), since the clinical use of cisplatin is still limited cause of the 
development of neurotoxicity and others undesirable effects. 
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Support materials: 
 
Sample preparation: 
 
Superoxide dismutase (SOD1) wt was overexpressed in the BL21 DE3 Origami plys 
E. coli strain. The fusion protein was obtained by growing the cells in minimal medium in 
shaking flasks at 37°C until OD600 reached 1 and then induced with 0.5 mM IPTG for 12 h at 
25°C. Protein was isolated by sonication in 20 mM Tris-HCl, 100 mM NaCl, 5 mM imidazole 
buffer at pH 8 and centrifuged at 40 000 RPM for 20 min. Purification was performed by 
affinity chromatography using a nickel chelating (His-Trap) column and digestion with 
AcTEV protease. Final step of purification was gel filtration, which was performed using the 
preparative column Sephadex 75 HiLoad 26/60 to separate the cleaved tag-protein. Protein 
purity was checked on a 17% polyacrylamide gel, and concentration was determined by 
optical spectroscopy. Demetallated hSOD1 was obtained by dialysis against 10 mM EDTA in 
50 mM sodium acetate pH 3.8. The chelating agent was removed by extensive dialysis against 
100 mM NaCl in the same buffer and then against acetate buffer alone, gradually increasing 
the pH from 3.8 to 5.5. 
Cis-diamminedichloroplatinum (II) (cisplatin) was purchased from Sigma-Aldrich. 
 
Spectroscopic characterization: 
 
Apo hSOD1 at 100 μM concentration (as dimer) was incubated alone, in the presence 
of cisplatinum and in the presence of cisplatinum together with small molecules (ADM_09 
and ADM_12 at 1 mM concentration) at 37°C in 20mM phosphate buffer at pH 7.0. The 
protein:cisplatinum ratio was 1:8, the protein:cisplatinum:small molecules ratio were 1:8:10. 
To monitor the formation of oligomeric species fluorescence spectroscopy was used and 
described in Banci et al. 2007 and Banci et al. 2008. The solution fluorescence emission was 
measured, over time of incubation, with a Cary 50 Eclipse spectrophotometer supplied with a 
single-cell Peltier thermostated cell holder regulated at 37˚C. Fluorescence was followed with 
ThT, a dye that binds to extended β-sheets, which is typical structural feature of amyloids 
(Biancalana & Shohei 2010; Naiki et al.1989). Free ThT has excitation and emission maxima 
at 350 and 450 nm, respectively. However, upon binding to amyloid-oligomers, the excitation 
and emission wavelengths change to 450 and 485 nm, respectively. Fifty-four microliter 
aliquots of sample were added to 646 µl of a 215 µM Tht solution in a 20 mM phosphate 
buffer at pH 7.0. The background fluorescence spectrum of the buffer was subtracted. The 
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excitation wavelength was 446 nm (bandwidth, 10nm), and the emission was recorded at 480 
nm (bandwidth, 10 nm). Fluorescence intensity at 483 nm was plotted against the time of 
incubation. 
Synthesis of the N-hydroxysuccinimido ester of -lipoic acid (Nativi et al. 2013): 
 
 
 
To a solution of lipoic acid (6.00 g, 29.1 mmol) and N-hydroxysuccinimide (4.02 g, 
34.9 mmol) in THF (150 mL) was added dropwise at 0 C° and under vigorous stirring, a 
solution of dicyclohexylcarbodiimide (DCC) (7.20 g, 34.9 mmol) in THF (15 mL). The 
addition was completed  in 15 min, after which the reaction mixture was allowed to warm to 
room temperature and stirred for 15 h. The precipitate obtained was filtered and the solution 
evaporated. The solid obtained by evaporation was suspended in ethyl acetate (100 mL) and 
the insoluble dicyclohexylurea was filtered off. Evaporation of the organic phase gave a 
yellow solid (9.03 g) that was treated with 80 mL of a mixture of hexane/ethyl acetate 1:1 to 
precipitate the N-hydroxysuccinimido ester of lipoic acid. The solid was collected by filtration 
(7.96 g, 90%) and was used in the next step without further purification. 
 
Synthesis of (2S)- 2-(3-(5-(1,2-dithiolan-3-yl)pentanamido)propanamido)- 
3-(4H-imidazol-5-yl)-propanoic acid – [ADM_09] ( Nativi et al. 2013):  
 
 
 
To a cooled (0 C°) and well stirred suspension of L-Carnosine (6.06 g, 26.8 mmol) and 
NaHCO3 (2.25 g, 26.8 mmol) in DMF/H2O 1:1 (100 mL) a solution of N-hydroxysuccinimido 
ester of lipoic acid (7.75 g, 25.5 mmol) in DMF (40 mL) was added dropwise in 30 min. The 
reaction mixture was allowed to warm to room temperature and stirred for 3 h. A TLC control 
S S
O
O N
O
O
S S
O
HN
O
HN
O
HO
N
NH
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showed the complete consumption of the reagent and the reaction was stopped and the 
organic solvent evaporated. The yellow solid obtained was suspended in toluene (110 mL), 
filtered, and dried on a G3 gooch by suction. The crude (10.7 g) was purified through flash 
column chromatography on silica gel (CH2Cl2/EtOAc/MeOH 2:1:1, then MeOH/ EtOAc 2:1) 
to give (2S)-2-(3-(5-(1,2-dithiolan-3-yl)pentanamido)propanamido)-3-(4H-imidazol-5-yl)-
propanoic acid (8.51g, 20.5 mmol, 81%) as a pale yellow solid. 
 
In vitro tests:  
 
Nitro Blue Tetrazolium (NBT) oxidation test.  
Superoxide anion was generated as reaction product between ipoxanthine (600 mM) 
and xanthine oxidase (10 mU/ml). The oxidation kynetic of nitro blue tetrazolium (NBT, 10 
mM) was spectrophotometrically measured at 560 nm in the absence or in the presence of 
ADM_09 and ADM_12 (0-1000 µM). Value are expressed as absorbance arbitrary units 
(A.U.) and the basal value of NBT oxidation was normalized to 100 U.A. (Ciuffi et al. 1998) 
 
Cell cultures.  
Primary cultures of astrocytes were obtained according to the method described by McCarthy 
e De Vellis (Bennett & Xie, 1988). Briefly, the cerebral cortex of newborn (P1-P3) Sprague 
Dawley rats (Harlan, Italy) were dissociated in Hanks’ balanced salt solution (HBSS) 
containing 0.5% trypsin/EDTA and 1% DNAse (Sigma, Germany) for 30 minutes at 37° C. 
The suspension was mechanical homogenized and filtered. Cells were plated in DMEM high 
glucose with 20% FBS. Confluent primary glial cultures were used to isolate astrocytes 
removing microglia and oligodendrocytes by shaking. The purity of astrocyte cultures were 
determined immunocytochemically by staining for GFAP (Dako, Denmark). Cells were fixed 
in 4% paraformaldehyde, then incubated with the antibody (1:200) and visualized using 
Alexafluor conjugated secondary antibody. Nuclei were stained with 4,6-diamidino-2-
phenylindole dihydrochloride (DAPI). GFAP-p ositive cells were 95-98% in astrocyte 
cultures. Experiments were performed 21 days after cell isolation. 
 
SOD-inhibitable superoxide anion (O2¯) production evaluated by cytochrome C assay.  
Astrocytes were plated in 6-well plates (5
.
10
5
/well) and grown in until confluence. 
Cells were then incubated with or without 100 μM oxaliplatin in serum-free DMEM 
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containing cytochrome C (1 mg/mL) for 4 hours at 37 °C, in the absence or presence of 10 
µM ADM_12. Non-specific cytochrome C reduction was evaluated carrying out tests in the 
presence of bovine superoxide dismutase (SOD; 300 mU/mL). The supernatants were 
collected, and the optical density was spectrophotometrically measured at 550 nm. After 
subtracting the non-specific absorbance, the SOD-inhibitable O2¯ amount was calculated by 
using an extinction coefficient of 2.1
.
10
4 
M
-1
cm
-1
 and expressed as µM/mg proteins/4 hours. 
The 4 hour incubation interval was chosen on the basis of preliminary experiments which 
showed poor reliability for longer cytochrome C exposure to the cellular environment.  
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Beta amyloid hallmarks: from intrinsically disordered proteins to Alzheimer's 
disease. 
A brief review. 
 
From the clinical basis of neurodegeneration to the molecular level of Alzheimer’s disease. 
A history of the discovery of beta amyloid protein and its proteolytic biogenesis. 
 
 
“You have to begin to lose your memory, if only in bits and pieces, to realize that memory is 
what makes our lives. Life without memory is no life at all, just as an intelligence without the 
possibility of expression is not really an intelligence. Our memory is our coherence, our 
reason, our feeling, even our action. Without it, we are nothing."  
Luis Bunuel 
 
 
Over 600 disorders afflict the nervous system (European Commission website 2014). 
Neurodegenerative diseases are defined as hereditary and sporadic conditions that are 
characterized by progressive nervous system dysfunction. These disorders are often associated 
with atrophy of the affected central or peripheral structures of the nervous system. They 
include diseases such as Alzheimer's disease (AD) and other dementias, brain cancer, 
degenerative nerve diseases, encephalitis, epilepsy, genetic brain disorders, head and brain 
malformations, hydrocephalus, stroke, Parkinson's disease, multiple sclerosis, amyotrophic 
lateral sclerosis (ALS or Lou Gehrig's Disease), Huntington's disease, and prion diseases. 
Neuroscientific research has enjoyed rapid progress fuelled by technologically sophisticated, 
multidisciplinary approaches. If we consider the vast amount of literature published on the 
subject of neurodegeneration just in the last years, we could notice a substantial progress in 
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understanding the molecular basis of these terrifying diseases, but what we know is still a 
drop in the bucket, and the main question remains: what causes neurodegeneration and how 
can we cope with it? 
In this short review we illustrate the emerging trend of defining several human 
neurodegenerative disorders as syndromes of protein folding and oligomerization through the 
example of AD. AD is recognized as a major public health problem in developed countries, 
and knowledge of its causes and mechanisms has grown enormously in the past decade. This 
insidious and devastating brain degeneration that robs its victims of their memory, reasoning, 
abstraction, and language abilities affects one in four individuals over 85 years of age. 
According to the World Alzheimer Report, the disease is expected to affect 115.4 million 
people by the year 2050 (Alzheimer’s Disease International website 2014). From an economic 
point of view, AD is one of the most expensive diseases because it usually spans many years 
and patients require intense daily care. 
Symptoms associated with the illness include cognitive dysfunction and neuronal death in the 
brain, both of which are indicative of a significant progressive neurodegenerative disease 
(Walsh and Selkoe, 2004). No effective treatments for AD are currently available and not 
even its pathogenesis is fully understood. The current limited number of treatments for 
Alzheimer's disease merely address symptoms rather than the root cause. The so-called 
“amyloid hypothesis” has come to dominate explanations for the damage that occurs to the 
brain.  The presence of amyloid plaques and congophilic angiopathy in the brain cortex and 
hippocampus is considered to be a major pathological feature of AD (Evin and Weidemann, 
2002).  Almost nine decades passed from the moment when Alois Alzheimer peered through a 
microscope at the brain of his first patient and prophetically wrote, “scattered through the 
entire cortex … one found miliary foci that were caused by the deposition of a peculiar 
substance …” ( Selkoe D. J. 1994) and when neuroscientists isolated and chemically 
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characterized the nature of the amyloid material found in the senile plaque, revealing the Aβ 
protein (Glenner and Wong, 1984; Masters et al. 1985) and its precursor APP (amyloid 
precursor protein) (Kang et al. 1987; Evin and Weidemann, 2002).  They observed that 
amyloid peptides constitute ~90% of the plaque material (Glenner and Wong, 1984; Masters 
et al. 1985; Kang et al. 1987), while the remaining 10% of amyloid plaques are composed of 
proteins from the apolipoprotein E class, lipids from membranes of degenerated portions of 
the intercommunicated nerve extensions called axons, metal ions such as Cu, Zn, Fe and Al, 
and traces of other components from the extracellular liquid. Transmission electron 
microscopy of amyloid plaques revealed numerous unbranched filaments, representing 
amyloid fibrils, surrounded by amorphous aggregates of diffuse amyloid. Amyloid plaques 
fall into two broad morphological categories: diffuse and neuritic. Both plaque types are 
detectable with anti-Aβ antibodies, but only neuritic plaques are prominently stained by sheet-
binding dyes such as Congo red and thioflavin S. Neuritic dystrophies are swollen and 
distorted processes of axonal or dendritic origin that radiate from the core of a neuritic plaque. 
They are detectable with antibodies against APP, phospho-tau, neurofilaments and ubiquitin, 
indicating a disruption of protein transport and attempts to degrade this blockage (Dickson et 
al. 1999). Progressive neuritic plaque deposition is a hallmark of AD. Neuritic plaque 
formation commonly begins in the neocortex and later affects the hippocampus and amygdala. 
By the end stage of the disease, neuritic plaques are present in the brainstem and other 
subcortical structures (Thal et al. 2002). It has been suggested that the presence and a 
substantial increase in diffuse plaque is associated with the preclinical stages of AD 
(Knopman et al. 2003; Vlassenko et al. 2011). The surprising and totally unexpected 
observation that Aβ is produced constantly throughout life as a physiologically normal 
metabolite generated in healthy people changed the common concept of AD (Hardy and 
Selkoe, 2002). Plaques have also been found in cognitively normal individuals, and plaque 
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burden does not correlate with memory decline. Moreover, successful removal of amyloid 
plaques by immunotherapy fails to improve cognition (Haass, 2010). Additionally, Dobson 
and co-workers have shown that virtually any protein can be induced into forming amyloid, 
suggesting that amyloid is a primordial, highly stable polypeptide form that had to be 
overcome by evolution in order to create functional globular proteins (Dobson, 2003). Soluble 
Aβ oligomers are now believed to act as neurotoxic entities rather than amyloid plaques. 
It appears that the soluble Aβ monomers require conversion to a largely β-pleated sheet 
conformation and subsequent aggregation before they can confer neurotoxicity in vitro 
(Lorenzo et al. 1994; Howlett et al. 1995). The production of the toxic species – soluble Aβ 
oligomers – and their subsequent ability to cause neuronal injury depends on the precision of 
an intramembranous proteolytic cleavage of APP (Haass and Selkoe 2007). Proteolytic 
processing of APP protein involves three types of proteases. 
APP is a member of an evolutionarily conserved gene family with two mammalian homologs, 
amyloid precursor-like proteins (APLP) 1 and 2 (Wasco et al. 1992, 1993). These proteins 
contain highly similar sequences in their ectodomains and intracellular carboxy-termini, but 
the transmembrane region comprising the Aβ peptide is unique to APP (Bayer et al. 1999). 
Although its primary physiological function remains unclear, APP has been implicated in a 
variety of processes such as intracellular signalling, synapse adhesion, trophic support, axon 
remodelling and apoptosis (Zheng and Koo, 2011). 
APP is ubiquitously expressed. There are three major APP isoforms resulting from alternative 
splicing of its 18 exon gene: APP695, APP751 and APP770 (Yoshikai et al. 1990). APP751 
and APP770 are the main transcripts found in non-neuronal tissue. APP695 is the most 
abundant isoform in the brain, where its expression is primarily limited to neurons. Brain 
region-specific variation in APP695 expression occurs in both mouse and human, with the 
highest transcript levels found in the cortex, hippocampus and cerebellum (Sola et al. 1993). 
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APP is processed via two major pathways that utilize different enzymes and result in distinct 
cleavage products. The non-amyloidogenic pathway precludes the formation of Aβ due to 
constitutive α-secretase-mediated cleavage in the middle of the Aβ domain (Esch et al. 1990). 
It was initially proposed that a zinc-dependent, transmembrane protease served as α-secretase 
(Roberts et al. 1994). Three members of the A disintegrin and metalloproteinase (ADAM) 
family were later found to possess α-secretase activity: ADAM-10, ADAM-17, and ADAM-9 
(Lammich et al. 1999). More recent evidence, however, suggests that ADAM-10 serves as the 
primary α-secretase in neurons (Kuhn et al. 2010). Alpha-cleavage of APP occurs mainly at 
the plasma membrane, releasing a soluble α-APP fragment (sAPP α) into the 
lumen/extracellular space and creating a membrane-bound, 83-residue C-terminal fragment 
(C83) (Sisodia, 1992). Subsequent intramembranous cleavage of C83 by γ-secretase liberates 
a soluble, 3 kDa fragment (p3) and the APP intracellular domain (AICD) (Zheng and Koo, 
2011). The p3 fragment is rapidly degraded, while AICD may act as a transcriptional 
regulator (Haass et al. 2007). 
The amyloidogenic processing of APP primarily occurs in the endocytic pathway. β-secretase 
initiates the sequence of amyloidogenic cleavage events. Cleavage of APP at the β-site 
generates a soluble amino-terminal fragment (sAPP β) and a membrane-associated, 99-
residue C-terminal fragment (C99). γ-secretase then performs a stepwise, intramembrane 
cleavage of the C99 fragment, liberating Aβ and AICD. Aβ peptides range from 37 to 43 
amino acids in length; however, under physiological conditions, the majority of Aβ produced 
is 40 amino acids long (Aβ40). The 42 amino acid variant (Aβ42) normally only comprises a 
minor fraction of the total Aβ. Nevertheless Aβ42 has a more hydrophobic nature, and its 
aggregative ability and neurotoxicity are therefore much greater than those of Aβ40; both of 
these forms (Aβ40 and Aβ42) are therefore targets of intense study (Haass et al. 2010). β-site 
cleaving enzyme 1 (BACE1) was identified as the enzyme responsible for APP β–cleavage. 
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BACE1 is a type 1 membrane-bound aspartyl protease with its active site facing the lumen. It 
is capable of cleaving APP at two positions: the aspartate at position 1 of the Aβ sequence or 
the glutamate at position 11. BACE1 is found in a variety of tissues, but is predominantly 
expressed in neurons (Sinha et al. 1999). Intracellularly, BACE1 mainly localizes to the trans-
Golgi network and endosomes. However, BACE1 is also trafficked between the Golgi and the 
plasma membrane, where it is enriched in lipid rafts. From the plasma membrane, BACE1 is 
internalized and sorted into endosomes or recycled to the trans-Golgi network (Walter et al. 
2001). It serves as the primary β-secretase and is the rate-limiting enzyme in Aβ production. 
There are currently four known components of γ-secretase: presenilin (PS1 or PS2), nicastrin, 
anterior pharynx defective 1 (APH1) and presenilin enhancer 2 (PEN-2). These proteins 
assemble into the γ–secretase complex while cycling through the endoplasmic 
reticulum/Golgi (Edbauer et al. 2003). Once mature, γ-secretase is primarily found at the 
plasma membrane and in the endosomal/lysosomal system. Although PS, nicastrin, APH1 and 
PEN-2 are all required for γ-secretase activity, PS contains the catalytic active site needed for 
γ-cleavage of APP (Edbauer et al. 2003).  
 
 
Figure 13.1. APP metabolism by the secretase enzymes (Barrantes et al. 2010). 
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Polymorphism widely observed for Aβ amyloidal aggregates in vitro. 
Aβ molecules can spontaneously self-aggregate in vitro into different species (Jan et al. 2010) 
under distinct conditions. Aβ peptides can form soluble oligomers and protofibrils, which 
could be intermediates of a fibrillation process (Fig. 13.2) (Benilova et al. 2012). Studies have 
revealed the high neurotoxicity of these species and their close links with AD (Benilova et al. 
2012; Chimon et al. 2007; Hoshi et al. 2003; Krafft and Klein, 2010; Kirkitadze et al. 2002; 
Lambert et al. 1998; Lesne´ et al. 2006; Noguchi et al. 2009; Selkoe, 2008). Instead, the 
formation of amyloidal deposits consisting of Aβ fibrils is a pathological hallmark of AD. 
Although mature amyloid fibrils are sometimes described as being predominantly neutral 
(Aksenov et al. 1996), there is evidence in some recent reports that Aβ fibrils are also 
neurotoxic and that the progression of AD symptoms is correlated with the amount of these 
insoluble Aβ assemblies (Chimon et al. 2007; Lorenzo et al. 1994; Meyer-Luehmann et al. 
2008; Petkova et al. 2005; Qiang et al. 2012; Selkoe et al. 2004; Walsh et al. 1999). 
 
Monomer          Dimer                    Oligomers                     Protofibrils                     Mature fibrils 
 
 
 
         Lag phase                                               Elongation phase 
 
Figure 13.2. A putative schematic of aggregation of Aβ with two kinetic phases. In the lag 
phase, monomers slowly form oligomers (dashed lines). In the elongation phase, oligomers 
promote fibril formation via protofibrils (straight line) (Kumar et al. 2011). 
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Besides the different types of aggregates, the morphology of the same type of Aβ assemblies 
can also vary significantly depending on different aggregation conditions. This phenomenon 
is typically called polymorphism and has also been found in samples derived from AD patient 
brain tissues (Paravastu et al. 2009; Lu et al. 2013). Furthermore, it has been shown that 
different morphologies of Aβ fibrils can cause changes in neurotoxicity (Petkova et al. 2005). 
Overview of functional polymorphism and structural models of amyloidal fibrils. 
The polymorphism of Aβ fibrils has been determined in vitro by numerous different structural 
studies such as cryo-electron microscopy (cryo-EM) (Fändrich et al. 2011; Meinhardt et al. 
2009), which revealed a large spectrum of Aβ40 fibril polymorphisms, and solid-state nuclear 
magnetic resonance (SSNMR) (Benzinger et al. 1998; Bertini et al. 2011; Lansbury et al. 
1995; Paravastu et al. 2008; Petkova et al. 2002, 2005, 2006; Qiang et al. 2011) in particular. 
SSNMR is one of the best techniques for obtaining atomic resolution structures of amyloid 
fibrils sufficient for the development of full molecular models (Tycko, 2010; Wasmer et al. 
2008), as X-ray crystallography is limited to small amyloidogenic peptides and cryo-EM is 
hindered by its relatively low spatial resolution. SSNMR has allowed for substantial 
advancement in understanding the structure of amyloid fibrils. Dipole-dipole couplings and 
chemical shift anisotropies are not averaged due to the absence of isotropic tumbling in solid-
state samples. As a result, linewidths in SSNMR spectra are broadened relative to solution-
state NMR, resulting in lower resolution. On the other hand, the absence of tumbling enables 
the study of the effects of anisotropic or orientation-dependent interactions. Cross polarization 
(CP), high-power proton decoupling, and magic-angle spinning (MAS) are used as standard 
techniques to obtain high-resolution SSNMR spectra. The isotropic chemical shift values 
obtained from CP-MAS experiments can be used to determine site-specific secondary 
structures. In fibrillar samples, CP-MAS is useful for observing rigid fibrillar parts, while 
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dipolar-dephasing MAS is used to detect soluble components of mobile parts (Naito et al. 
2004).  Rational resonance is used for determining homonuclear-internuclear distances, and 
rational echo double resonance (REDOR) is used to determine heteronuclear-internuclear 
distances (Tycko and Ishii, 2003). Other techniques, such as radiofrequency-driven recoupling 
and dipolar-assisted rational resonance, are useful for obtaining folding information on 
amyloid fibrils (Balbach et al. 2002). 
The only restriction of high-resolution studies of Aβ assemblies by SSNMR is the 
requirement for highly ordered and homogeneous samples. However, in amyloid systems it is 
rather common that several differently shaped aggregates coexist in a mixture, making 
preparation of the samples very difficult. This limitation can be overcome by programmed 
isotopic labelling schemes or sequence truncation, but each of these methods hampers 
complete structural analysis by SSNMR. Another strategy to overcome this restraint is the so-
called seeding procedure, which leads not only to an improvement in the homogeneity of Aβ 
fibrils, but also permits insights into the molecular structures of amyloid fibrils developing in 
human tissue. This tactic is feasible after reconstruction of isotope enriched in vivo fibrils  
using brain tissues as seeds from patients with AD (Paravastu et al. 2009). This approach is 
made possible by the fact that in vitro studies have shown that the seeding procedure allows 
fibrils to be obtained that exactly retain the same molecular structures, corresponding to the 
seeds from the brain of patients with AD (Paravastu et al. 2008; Petkova et al. 2005). This 
strategy also has many drawbacks because the sample obtained in this way might contain 
significant contamination from many tissue components such as lipids. However, it allows the 
restoration of pathological samples from AD patients and the obtainment of high-resolution 
structural characterizations of these assemblies. 
As heterogeneity also depends heavily upon different aggregation conditions, several different 
factors must be taken into consideration. One important key factor is the purity of the starting 
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materials. The presence of pre-existing aggregates can result in a lack of reproducibility, as 
well as in changes of kinetics, fibrillogenesis processes, and neurotoxic activity (Fezoui et al. 
2000). Several different protocols have been developed in order to solve this issue, resulting 
in standardized aggregate-free Aβ peptide samples (Broersen et al. 2011, Jao et al. 1997, 
Fezoui et al. 2000). Disaggregation of the Aβ assemblies involved the use of the structure-
breaking organic solvents hexafluoroisopropanol (HFIP) and dimethyl sulfoxide (DMSO), 
trifluoroacetic acid (TFA) pre-treatment, and pre-dissolution of the peptide in a dilute base 
solution (e.g. NaOH). Each of these approaches allows aggregate-free material to be obtained. 
Another significant aspect is represented by the conditions of the fibrillation protocols such as 
concentration, pH, ionic strength, and temperature. The incubation of the sample in quiescent 
conditions leads to fibrils with the “twisted pairs” morphology (Paravastu et al. 2008), while 
gentle agitation results in striated ribbons (Petkova et al. 2006) or “flat” striated bundles 
(Bertini et al. 2011). The appropriate selection of the fibrillation strategy is essential for 
obtaining high quality samples for high resolution SSNMR. 
Aβ40 amyloid fibrils have been widely investigated and several structural models have 
recently been proposed using SSNMR (Bertini et al. 2011; Paravastu et al. 2008; Petkova et 
al. 2002, 2006), A structural model of Aβ42 fibrils was proposed based on solution NMR and 
mutagenesis (Lührs et al. 2005). 
In all these fibrillar assemblies Aβ molecules are densely packed in extended β-sheets 
(ladders) but exhibit polydispersed morphology and differ from one another in length and 
bundle width. Mature fibrils are characterized by a specific filamentous structure and usually 
contain 2–6 protofilaments that are more than 1 μm long and 8–12 nm in diameter. They 
display a cross-β X-ray fibre diffraction pattern as well as stainability with Congo red, 
resulting in green birefringence; they also bind Thioflavin-T (Merz et al. 1983; Petkova et al. 
2005; Serpell, 2000). It is widely accepted that amyloid fibrils are insoluble deposits, but 
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recent studies have shown that many biochemical factors, e.g. biological lipids, are able to 
efficiently revert the fibrillation process and convert these insoluble assemblies into soluble, 
highly toxic intermediate species that retain the same biochemical and biophysical properties 
(Martins et al. 2008).  
The distinct polymorphism of fibrillar assemblies is reflected in variations in overall structural 
symmetry and differences in specific aspects of structural elements and various residue sites, 
as well as in the nature of β-sheet structures including topologies of the β1-turn-β2 motif and 
inter-protofilament contacts (Ahmed et al. 2010; Bertini et al. 2011; Lührs et al. 2005; 
Paravastu et al. 2008; Petkova et al. 2006) (Fig. 13.3). Recent studies have also shown that, in 
Aβ fibrils carrying mutants, both parallel and anti-parallel registry can occur (Qiang et al. 
2011). 
Although the structural polymorphism of Aβ40 fibrils was initially described as taking place 
mainly at the supramolecular level (Paravastu et al. 2008), a recent structural model of mature 
Aβ fibrils (Bertini et al. 2011) suggests that polymorphism can already originate at the level 
of the zipper of the β1-turn-β2 motif, the inter-protofilament interface and the N-terminal 
conformation. The N-terminal part of the peptide in the fibril model can adapted βN-strand, 
but there is also evidence in the literature that a disordered conformation on the N-terminal 
part in some other Aβ fibrils is also possible (Paravastu et al. 2008; Petkova et al. 2006; 
Sachse et al. 2008, 2010). It can therefore be concluded that the N-terminal part of Aβ40 
peptides can adopt distinct conformations and thereby also contribute to structural diversity. 
It is reasonable to speculate that the folding of the monomer and supramolecular packing 
(within and among protofilaments) are linked or even define the morphology of amyloid 
fibrils through structural duplication/propagation along the fibril axis similar to the growth of 
1D nanomaterials (Bertini et al. 2011). 
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Figure 13.3. Different topologies of β1-turn-β2 motif (left column) and inter-protofilament 
contacts (right column) in various SSNMR-derived structural models of Aβ fibrils ((a) Bertini 
et al. 2011; (b) Petkova et al. 2002; (c) Petkova et al. 2006; Paravastu et al. 2008; (d) Ahmed 
et al. 2010)). Adapted from (Bertini et al. 2011). 
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Review of the methods for immobilizing and investigating amyloidal intermediate species 
Since various studies had reported that the neurotoxicity of Aβ peptides might be ascribed to 
pre-fibrillar assemblies  (i.e. not necessarily fibrils (Benilova et al. 2012; Chimon et al. 2007; 
Hoshi et al. 2003; Kirkitadze et al, 2002; Krafft and Klein, 2010; Lambert et al. 1998; Lesne´ 
et al. 2006; Noguchi et al. 2009; Selkoe, 2008)), the high-resolution structural characterisation 
of these soluble species has become an overarching objective for understanding Aβ 
aggregation pathways and the complex molecular mechanism of AD (Benilova et al. 2012). 
Several in vitro SSNMR studies established an initial high-resolution insight into certain non-
fibrillar (Ahmed et al. 2010; Chimon et al. 2005, 2007; Lopez del Amo et al. 2012) and 
protofibrillar (Qiang et al. 2012; Scheidt et al. 2011) Aβ aggregates. Several other 
experimental and theoretical methods have also been used to obtain residue-specific 
information on prefibrillar Aβ aggregates and on structural persistence in the monomer 
(Bernstein et al. 2009; Bertini et al. 2013; Danielsson et al. 2006; Fändrich et al. 2012; Fawzi 
et al. 2011; Gallion 2012; Haupt et al. 2012; Kheterpal et al. 2006; Pan et al. 2011). 
These prefibrillar intermediate assemblies, e.g. oligomers, protofibrils, and Aβ-derived 
diffusible ligands (ADDLs), as well as Aβ annular assemblies, are likely involved in amyloid 
fibril formation. All of these assemblies are rich in β-sheet structure and bind Congo red and 
Thioflavin-T, although more weakly than mature fibrils (Jan et al. 2010).   
However, an investigation of these prefibrillar deposits faces many obstacles. As they are 
often thermally unstable compared to mature fibrils, many different methods to immobilize 
and study these species have been developed in recent years and each strategy has its own 
advantages and disadvantages. 
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Pioneering work in this direction has been performed by the groups of Smith and Ishii 
(Ahmed et al. 2010; Chimon et al. 2005, 2007), who focused on the Aβ oligomeric form. 
Taking advantage of the fact that various proteins including Aβ retain their structures after 
lyophilisation (Benzinger et al. 1998; Petkova et al. 2002; Studelska et al. 1997), many groups 
trap the thermally labile intermediate by freeze-trapping and subsequent lyophilisation. 
Different methods of trapping oligomeric and protofibrillar Aβ species were used such as 
filtration through low molecular weight cut off filters (Bitan et al. 2005), photo-induced 
crosslinking of unmodified proteins (Bitan et al. 2003), organic solvents (Haupt et al. 2012), 
density gradient centrifugation (Ward et al. 2000), size exclusion chromatography (SEC) 
(Bitan et al. 2003; Hartley et al. 1999; Jan et al. 2010; Walsh et al. 1997) and interaction 
partners (Bieschke et al. 2012; Lopez del Amo et al. 2012; Scheidt et al. 2011). 
A method termed sedimented solute NMR (sedNMR) has recently been developed and allows 
Aβ aggregates to be collected and trapped in a fully hydrated environment without adding 
cosolvents or interaction partners, therefore providing a unique way to access the formation 
kinetics and structural features of these species with reduced perturbations (Bertini et al. 
2013). 
In this method, solid-state NMR (SSNMR) experiments are used to observe proteins that are 
sedimented from solution using an ultracentrifugal field (Bertini et al. 2011, 2012, 2012, 
2013; Gardiennet et al. 2012; Polenova 2011; Ravera et al. 2013). The application of SSNMR 
is possible, as it has been reported (Ahmed et al. 2010; Bernstein et al. 2009; Fawzi et al. 
2011; Kirkitadze et al. 2002; Lee et al. 2011) that Aβ peptides in aqueous solutions 
spontaneously form soluble aggregates of high molecular weight (50–200 kDa) that are large 
enough to sediment and thus become visible by SSNMR. 
Sedimented solute NMR relies on the fact that sedimented macromolecules may be 
rotationally impaired by self-crowding, thus giving rise to solid-state NMR spectra. The 
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sedimentation of macromolecules into this type of solid-like phase can be achieved in two 
different ways. One way is direct in situ sedimentation by magic angle spinning (MAS) of the 
NMR rotor (MAS-induced sedimentation), which acts as an ultracentrifuge (Bertini et al. 
2011) (Fig. 13.4A). In situ SedNMR can be used to address the kinetics of formation of 
soluble Aβ assemblies by simultaneously monitoring the disappearance of the monomer and 
the appearance of the oligomers. Another method is ex situ sedimentation by common 
ultracentrifuge (UC-induced sedimentation) (Bertini et al. 2012; Gardiennet et al. 2012) with 
the help of devices designed to pack NMR rotors with precipitates or microcrystals 
(Böckmann et al. 2009) (Fig. 4B). Ex situ sedNMR allows one to select different oligomeric 
species by changing experimental conditions such us ultracentrifugation frequency or time 
and the initial Aβ peptide concentration. 
Sedimentation through ultracentrifugation, either by magic angle spinning (in situ) or 
preparative ultracentrifugation (ex situ), can be used to immobilize and characterize 
oligomeric species, measure their formation kinetics, selectively sediment some of these 
species by their different molecular weights, and reveal the atomic-level structural features of 
soluble Aβ assemblies. 
The collective data obtained from all of these methods demonstrate probable pathways from 
these fibril precursors to terminal fibrillar states and also provide evidence that these 
prefibrillar assemblies already contain β-strand structures but with different supramolecular 
organizations and reduced structural order and periodic symmetry, which might define the 
structures of the multiple conformers in fibrils in amyloid misfolding. However, some authors 
have suggested that certain oligomers that do not further aggregate to amyloid fibres and that 
have different secondary structures exist among different Aβ intermediate species. 
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Figure 13.4. Representation of the sedimentation process. In magic angle spinning-induced 
(in situ) sedimentation (top), the sediment is created in a thin layer at the rotor walls (the 
width of the sediment layer is greatly exaggerated). Sedimentation induced by preparative 
ultracentrifugation (ex situ) (bottom) can be used to effectively fill the rotor with sediment. 
Adapted from (Bertini et al. 2013). 
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Association between neurotoxicity and different ratios of Aβ40 to Aβ42 
Aside from the fact that neurotoxicity can be induced by intermediate deposits, recent studies 
have established that the ratio of Aβ40 to Aβ42 is an important factor for providing stability 
to intermediate, neurotoxic species and affecting aggregation kinetics (Frost et al. 2003; 
Herzig et al. 2004; Jan et al. 2008, 2010; Kim et al. 2007; Kuperstein et al. 2010; Pauwels et 
al. 2012; Snyder et al.; Wang et al. 2006; Yan and Wang, 2007; Yoshiike et al. 2003; Younkin 
et al. 1995; Zou et al. 2003). 
Aβ42 and Aβ40 alloforms co-exist in a molar ratio of 1:9 under normal physiological 
conditions in the brain. In patients with familial AD this ratio is shifted to a higher level of 
Aβ42, corresponding to a ratio of 3:7. Investigations of the properties of the Aβ40/Aβ42 
mixture by different groups have clearly shown that these two species interact and change 
each other’s dynamic behaviour. Even minor alterations in the relative amount of the 
Aβ42/Aβ40 ratio dramatically affect the biophysical and biological properties of the Aβ 
mixtures reflected in their aggregation kinetics by altering the pattern of oligomer formation. 
It has been shown that Aβ40 delays Aβ42 aggregation, while Aβ42 has an opposite effect and 
induces Aβ40 aggregation. This observation was also confirmed by in vivo studies, which 
have shown that a higher percentage of Aβ40 peptides in the brain might be protective (Kim 
et al. 2007; Wang et al. 2006). 
Although it is generally assumed that alterations in ratios of the Aβ40 and Aβ42 mixture can 
stabilize distinct intermediate species associated with toxicity, the possibility that 
neurotoxicity is induced by a number of different conformations should not be neglected. This 
possibility can be explained by the fact that those toxic intermediate deposits might exist in 
dynamic equilibrium through their assembly and disassembly.  
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Since neurotoxic conformation(s) might by induced by a particular ratio of Aβ40 to Aβ42 a 
detailed structural characterization of Aβ40:Aβ42 mixed fibrils is needed. Investigation of the 
structure of Aβ40:Aβ42 mixed fibrils in different molar ratios might shed light on the 
processes related to the onset of the disease and on their correlation with Aβ peptides 
reciprocal ratios. 
 
Conclusions 
Although the direct involvement of Aβ peptides in AD is well documented, the toxic Aβ 
species and the precise mechanism of its neurotoxicity remain unclear. Moreover, there is still 
a significant gap between site-specific structural information and the complex structural 
diversity of Aβ amyloids. A detailed structural and functional characterization of fibrillar 
assemblies as well as the various prefibrillar intermediates is crucial for understanding Aβ 
aggregation pathways and identifyingtoxic Aβ species. The recognition of the real culprit for 
AD onset is fundamental for the design of new, effective therapeutic strategies targeted at 
preventing the formation or impairing the activity of toxic Aβ assemblies involved in AD. 
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Short summary of expression and purification procedures for the preparation of Aβ 
peptides 
 
Below we describe the methods of sample preparation of different kinds of Aβ peptides for 
NMR investigations. 
The AβM40 and AβM42 peptides without any fusion tags, as well as Aβ40 and Aβ42 without 
the starting methionine fused with an N-terminal hexahistidine affinity tag were expressed as 
inclusion bodies in E. coli. Although inclusion bodies are usually undesirable due to problems 
with protein refolding, they are a good alternative in the case of intrinsically disordered 
proteins because their separation from the cell lysate is an easy and efficient protein 
purification method. 
 
Aβ peptides with Met 
The cDNA of AβM40/AβM42 was cloned in the pET3a vector using the NdeI and BamHI 
restriction enzymes. The peptides were expressed in the BL21(DE3)pLys E. coli strain. The 
presence of an exogenous N-terminal methionine, due to the translation start codon, as 
reported in the literature (Walsh et al. 2009), does not affect the fibrillation kinetics or 
morphology of the fibrils formed by AβM40 or AβM42. 
Many papers report the expression conditions for Aβ peptide production as follows: 8 to 16 h 
of incubation after induction with the addition of 0.8 – 1 mM of isopropyl β-D-1-
thiogalactopyranoside (IPTG) and a temperature of 25-27˚C (Long, Cho, and Ishii 2011; 
Zhang et al. 2009). In order to increase the protein yield, especially in terms of labelled 
protein production, we tried to increase the variable cell culture parameters as much as 
possible, boosting protein expression as an insoluble fraction. Expression of the fusion 
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constructs under control of the T7 promoter/lac operator in E. coli BL21(DE3) cells provides 
high yields of the fusion proteins, which accumulate in inclusion bodies.  
In the case of AβM40/AβM42 the growth was performed using the Marley method (Marley, 
Lu, and Bracken 2001). The cells transformed with the AβM40/AβM42 expression plasmid 
were predominately grown in rich medium at 37°C until OD600 reached 0.6, then centrifuged 
and exchanged into an isotopically defined minimal media enriched with (15NH4)2SO4 (1 g/L) 
and (
13
C) glucose (4 g/L). The peptide expression was induced with 1.2 mM IPTG and the 
cells were harvested after 4 hours of incubation at 39°C.  
The peptides were purified as reported (Bertini et al. 2011; Hellstrand et al. 2010; Jan, 
Hartley, and Lashuel 2010; Walsh et al. 1997; 2009) with some modifications using a 
combination of anion exchange and size exclusion chromatography. All the manipulations 
were performed at slightly alkaline pH in order to avoid the formation of structural 
contaminants produced by isoelectric precipitation. 
There are some reports in the literature regarding possible aggregation and as a consequence a 
decrease in protein yield in pre-packed purification columns versus free resin (Walsh et al. 
2009; Zhang et al. 2009). We also observed that purification of AβM40 and AβM42 by ion 
exchange chromatography in column mode (diethylaminoethyl (DEAE) cellulose column) led 
to much lower yields of monomeric peptide than in batch mode because of protein 
precipitation and aggregation.  
The inclusion bodies were first solubilized with 8 M urea and then purified by ion exchange 
chromatography performed in batch mode. For this purpose DE52 resin on a Büchner funnel 
with filter paper on a vacuum glass bottle was used. Elution was performed using different 
concentrations of NaCl buffer. The protein was eluted with a 125 mM concentration of the 
salt. In the case of AβM42, the protein was also present in 20 mM, 150 mM, 200 mM and 1M 
fractions, probably due to progressive sample aggregation. All the obtained fractions of 
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diluted protein were concentrated to the final volume using an Amicon device. We examined 
a number of methods to concentrate the Aβ solution. Although several different methods 
within the 3 kDa molecular mass cut-off for centrifugal devices proved useful, the Amicon 
device was the best solution for highly concentrated proteins. 
This two-step purification allows a highly pure product to be obtained with a yield of about 10 
mg of AβM40 and 5-10 mg of AβM42 per litre of culture. 
 
Aβ peptides without Met 
Aβ40 and Aβ42 were produced in E. coli cytoplasm as fusion proteins with N-terminal 
hexahistidine affinity tags. The fusion construct consists of a soluble polypeptide segment 
comprised of 19 repeats of the tetrapeptide sequence NANP, a TEV protease cleavage site 
(sequence ENLYFQ), dipeptide linker sequences and the Aβ sequence. 
We applied a similar approach for the expression and purification of Aβ peptides (Aβ40 and 
Aβ42) without methionine. Cells were grown in rich medium (lysogeny broth (LB) or Terrific 
Broth (TB)) until they reached high OD values. Peptide expression was induced with 1-1.2 
mM IPTG and cells were harvested after 4 hours incubation at 39°C. After the removal of the 
soluble proteins the inclusion bodies were solubilized with 20 mM TRIS pH 8, 8M and 
purified by affinity chromatography using a nickel chelating (His-Trap) column under 
denaturating conditions, followed by digestion with AcTEV protease.  In order to avoid 
protein aggregation and improve the separation of cut/uncut protein, 8 M urea or 6 M 
guanidine hydrochloride was introduced in two affinity column steps. 
As a final purification step for both peptide families (Aβ40,42; AβM40,42), a gel filtration in  
50 mM ammonium acetate pH 8.5 using a Superdex 75 26/60 column was used. It is 
important to keep the pH of the solution over 4-7, the pH range where aggregation is 
maximized. 
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The aggregation of Aβ peptides is strongly influenced by the presence of structural and 
chemical impurities; therefore, before proceeding with SEC, all samples were denatured using 
6 M guanidine hydrochloride as described previously (Walsh et al. 1997).  
The protein obtained was dialysed in water and lyophilised.  
In the case of Aβ42 peptides and even more so with their mutants, due to problems with tag 
digestion, we have to adopt a different purification procedure, introducing organic solvents. 
The inclusion bodies were solubilized with 6 M guanidinium chloride and the protein was 
purified by metal chelating affinity chromatography on Ni2+-nitrilotriacetic acid agarose in 
the presence of 6 M guanidinium chloride, thus lowering the pH. The fusion proteins were 
further purified via reversed phase high-performance liquid chromatography (RP-HPLC) 
using a semi-preparative Zorbax SB300 C8 column (Agilent), lyophilized from aqueous 
acetonitrile and directly used for TEV protease cleavage. A cleavage efficiency of about 70% 
was achieved after incubation at pH 8.0 and 4°C for 16 h at a protein concentration of 100 μM 
in the presence of 5 μM TEV protease. The cleavage mixture was subsequently applied to RP-
HPLC, which allowed quantitative separation of the hydrophobic Aβ42 peptide from the 
other, more hydrophilic components in the cleavage reaction. The final yield of purified Aβ40  
was 20 mg/L of culture. 
Another problem encountered was associated with solubilisation of lyophilised protein in 
water. Because the Aβ peptides undergo time- and concentration-dependent aggregation in 
acetonitrile-water (Shen and Murphy 1995), the dry, purified peptides adopt different 
structures and aggregation states (Soto et al. 1995). Depending on the peptide batch and the 
particular aggregation conditions, considerable discrepancies exist across different 
laboratories as well as within the same laboratory over time. In addition, numerous studies 
have established that neurotoxicity and the kinetics of aggregation are directly related to 
assembly state in solution. Therefore, direct solubilisation of the Aβ peptides in aqueous 
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media should always be avoided because it generates batch-dependent mixtures of aggregates 
and structures (Hou et al. 2004). 
A couple of procedures have been proposed to disaggregate the Aβ and generate a monomeric 
random coil structure: pre-dissolution of the peptide in dilute base solution, and pre-
dissolution in TFA and HFIP solvents (Jao et al. 1997). Finally, we applied a protocol that has 
already been reported (Broersen et al. 2011) for the solubilisation of Aβ peptide that involves 
sequential solubilisation using the structure-breaking organic solvents HFIP and DMSO 
followed by column purification and results in standardized aggregate-free Aβ peptide. As 
was reported in pure DMSO, Aβ appears to be monomeric and lacks any β-sheet character 
(Shen and Murphy 1995). 
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Recombinant IDPs for NMR  
Tips and tricks 
 
It is becoming evident that intrinsically disordered proteins (IDPs) are not fully disordered, 
but have all sorts of transient, short, and long-range structural organisations that are function-
related. 
The structural and functional study of biomolecules is a highly interdisciplinary field that 
requires a correlation between different biophysical techniques. Although at first glance the 
study of IDPs seems very similar to the traditional analysis of structured proteins, specific 
skills and different approaches are needed to undergo IDP characterization (Uversky 2011). 
Structural biology requires a large number of steps to convert DNA sequence information into 
protein samples, including cloning, expression and purification strategy. The following is 
intended to assist in the sample preparation of IDPs from genome browsing to sample 
preparation and analysis. Different methodologies will be addressed with special tips and 
tricks highlighted that are helpful for overcoming common drawbacks/barriers usually found 
when working with IDPs.  
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Genome browsing and bioinformatics analysis 
 
Intrinsic structural disorder is a widespread phenomenon, especially in eukaryotes, where 
conservative bioinformatics predictions suggest that 5%–15% of proteins are IDPs, and about 
35-50% of proteins have intrinsically disordered regions (IDRs) longer than 30 residues 
(Ward et al. 2004). It has been accepted that disorder is needed for signalling among various 
living systems, and increases with organism complexity (Dunker and Obradovic 2001). 
Indeed, 75% of the signalling proteins in mammals are predicted to contain long disordered 
regions (Dunker et al. 2008).  
The web tools currently available are incredibly easy to use and, in most cases, very accurate 
information can be obtained quickly. Advanced genome tools for studying biology made an 
incredible amount of biological data available with a concomitant proliferation of biological 
databases and web software tools, i.e. data banks containing information on DNA, protein 
sequences, expression profiles, protein ensembles and structures. One example is the recently 
created protein ensemble database for IDPs (Varadi et al. 2013).  
The first step to start the work with a new protein is the sequence analysis, both if you are a 
protein hunter looking for an interesting target to study, as well if you’ve just joined a 
scientific work already ongoing. First of all analysis of the DNA sequence through 
bioinformatic tools might be helpful to order the synthetic gene of your target protein 
specifically adapted to the expression system of choice. Later on you can analyze the domain 
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composition, presence of signal peptide and inert-membrane helixes, as well as disorder 
regions in order to create suitable expression constructs. Even if the bioinformatic analysis is 
just the prediction, anyway it can be useful in order to get the preliminary information of the 
target protein. In case of IDPs the prediction of disorder domains is essential. 
A number of approaches have been developed to predict regions of protein disorder. These 
methods can be broadly classified into several different categories: ab initio, clustering and 
meta or consensus. 
The majority of these predictors are available through public servers, and links to many of 
them can be found in the "Disordered Protein Database" (Disprot)
1
, (Sickmeier et al. 2007), 
the "Database of Disordered Protein Prediction" (D
2
P
2
)
2
 (Oates et al. 2013), and in the 
recently created IDPbyNMR website
3
  
The big group of a prediction methods belong to the ab initio group and depend almost 
exclusively on sequence information. In other words, nothing more than the primary sequence 
is needed in order to make a prediction. Disordered regions in proteins are predicted using 
features extracted from the primary sequence in conjunction with statistical models. In 
clustering methods, tertiary structure models are predicted for the target protein, and then 
these models are superimposed by carrying out structural alignments. 
The generation of disorder prediction tools started from a comparison between the amino acid 
sequences of IDPs and those of structured globular proteins, which resulted in a number of 
significant differences including amino acid composition, sequence complexity, 
hydrophobicity, aromaticity, charge, and flexibility (Dunker et al. 2001). For example, IDPs 
are significantly depleted in hydrophobic (Ile, Leu, and Val) and aromatic (Trp, Tyr, and Phe) 
                                                          
1 http://www.dabi.temple.edu/disprot/index.php 
2 http://d2p2.pro 
3 http://www.idpbynmr.eu/home 
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amino acid residues, which form and stabilize the hydrophobic core of folded globular 
proteins. These residues are called order-promoting amino acids. On the other hand, 
IDPs/IDRs are substantially rich in polar (Arg, Gln, Glu, Lys, and Ser) and structure-breaking 
(Gly and Pro) disorder-promoting amino acid residues (Dunker et al. 2001; Radivojac et al. 
2007). Among the twenty common amino acid residues, proline is the most disordered-
promoting (Theillet et al. 2013).  The accuracy of predictors is regularly assessed as part of 
the Critical Assessment of Structure Prediction (CASP) experiment (Monastyrskyy et al., 
2011). It is therefore now possible to predict the tendency of a polypeptide chain to be 
disordered based on its primary sequence with an approximate accuracy of 80% (He et al., 
2009).  
To obtain more accurate disorder predictions, a good option is the use of meta predictors such 
as PONDR-FIT (Xue et al., 2010), which combine the output of several individual predictors. 
After obtaining the preliminary view of your sequence with information about folded and 
unfolded regions, you can think about creating the set of constructs, omitting unfolded 
regions, shortening the last ones, or simply substituting some amino acid so as to increase 
order. 
Tip 1 – Consider the possibility of creating different domain constructs as well as the full-
length construct. 
IDPs are often able to bind to different partners or to act as hub proteins, and in this way play 
an important role in a variety of different processes.  IDPs are particularly relevant for viruses, 
which need to exploit simple amino acid sequences (short linear motifs, SLiMs), which are 
well-exposed and ready to function, in order to interact with crucial key proteins from the host 
organism. They are also known as molecular recognition features (MoRFs) and different tools 
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for their prediction are available such as SLiMfinder
4
 (Davey et al. 2010), MoRFpred
5
 
(Disfani et al. 2012) and Anchor
6
 (Mészáros, Simon, and Dosztányi 2009). 
Using the BLAST alignment it is possible to establish the homology of the target protein with 
some proteins with known three-dimensional structure.  In this case one can consider the use 
of the MODELLER software to generate a homology comparative structural model of the 
target protein. The development of comparative software allows the study of the homology 
modelling of the protein's three-dimensional structures (Eswar et al. 2006). With this tool, the 
user provides a sequence alignment of the protein of interest and obtains a model based on 
known related Protein Data Bank (PDB) structures. For example, a model containing all of 
the non-hydrogen atoms calculated by comparative protein structure modelling based on the 
satisfaction of spatial restraints can be obtained using MODELLER (Šali and Blundell 1993). 
MODELLER also performs de novo modelling of loops in protein structures, multiple 
alignments of protein sequences and structures, optimization of various models of protein 
structure with respect to a defined objective, searching of sequence databases, clustering, 
comparison of protein structures, and so on.  
Once the protein sequence has been defined, the easiest way to obtain the corresponding gene 
is by ordering the synthesized gene of interest suitable for your expression system. With the 
development of new instruments that facilitate the production of biological material, the 
synthesis of genes containing the DNA sequence of a target protein is now feasible. Many 
companies such as Invitrogen's GenArt®, OriGene, Eurofins MWG Operon, GenScrip, and 
DNA2.0 among others provide web tools to order these genes, with several possibilities and 
strategies, including the optimization of the codons for the specific expression organism. It is 
important to highlight that the over-expression of human proteins in E. coli systems could be 
                                                          
4 http://bioware.ucd.ie/~compass/biowareweb/Server_pages/slimfinder.php 
5 http://biomine-ws.ece.ualberta.ca/MoRFpred/index.html 
6 http://anchor.enzim.hu 
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compromised, resulting in low expression yields, if the open reading frame (ORF) of the 
protein contains codons infrequently used by E. coli, the so-called "rare codons". In particular, 
codons for arginine (AGG, AGA, CGA), isoleucine (ATA), leucine (CTA) and proline (CCC) 
should be avoided (Schenk et al. 1995). Different web tools, such as those offered by 
Genscript
7
 and the United States National Institutes of Health (NIH)
8
, are available to check 
the presence of rare codons related to the desired expression system. Nevertheless, the gene of 
interest can be directly cloned from the organism cDNA, if available. The cloning strategy 
should be designed carefully, as it could be the basis of a successful work.  
Tip 2 – IDPs usually have a high proline content. Avoid rare codons in the DNA sequence, as 
they could lead to a low expression yields. 
 
Expression plasmid generation 
The standard procedure to express a recombinant protein is to carry out a screening of 
different constructs to identify the most efficient conditions for downstream purposes. The 
first step of the cloning process consists of the amplification of the target gene from a DNA 
template or plasmids through a polymerase chain reaction (PCR) using specific primers. After 
purification, the amplified product is inserted into a specific expression vector. Different 
vectors may be selected in order to obtain native protein or protein fused with different tags. 
The tags vary in size starting from 6-His to fusion proteins of 10-20 kDa o even 40 kDa 
proteins such as maltose-binding protein (MBP). They can enhance the expression level, 
increase solubility, and be very useful for the subsequent purification procedure due to their 
chemical properties (Esposito and Chatterjee 2006). Later on these tags may be removed by 
                                                          
7 http://www.genscript.com/cgi-bin/tools/rare_codon_analysis 
8 http://nihserver.mbi.ucla.edu/RACC/ 
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proteolytic cleavage with specific enzymes such as factor Xa, enterokinase (EK) or tobacco 
etch virus (TEV) protease (Arnau et al. 2006; Malhotra 2009). 
Tip 3 – Even if the tags are considered a good strategy, always consider expressing the native 
protein sequence. 
The classic method to insert an amplified PCR product into a vector is to use restriction 
enzymes that cleave DNA at specific recognition sites. Both the DNA and the cloning vector 
have to be treated with two restriction enzymes that create compatible ends. Later on these 
ends are joined together by a ligation reaction performed by the bacteriophage T4 DNA 
ligase. Finally an aliquot of the product of the reaction is transformed in DH5α E. coli 
competent cells and positive clones are screened by PCR screening followed by DNA 
sequencing. However, the classic cloning strategy is sometimes not feasible for the 
preparation of different constructs in parallel due to the lack of the suitable restriction sites 
common for the target gene and available vectors. Together with low efficiency and false 
positive clones, this technique is not the best for high-throughput cloning. Therefore, other 
cloning strategies have been developed that exploit ligation-independent cloning such as 
Gateway
®
 (Invitrogen) and most recently Electra
TM
 (DNA2.0) (Katzen 2007). 
Tip 4 – Many companies offer the possibility to clone the synthetic gene directly into a 
desired expression plasmid.  
Gateway
®
 cloning technology has been one of the most used strategies and enables rapid and 
highly efficient simultaneous transfer of DNA sequences into multiple vector systems for 
protein expression and functional analysis while maintaining orientation and reading frame. It 
basically consists of the generation of an expression silent entry clone that can be further 
recombined in the several expression vectors without the use of any restriction enzyme, taking 
advantage of the site-specific recombination properties of bacteriophage lambda. There are 
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many ways to create an entry clone but the most straightforward method is directional TOPO
®
 
cloning. The ligation reaction of the PCR product to the pENTR vector is accomplished by 
topoisomerase I. After isolation of the entry clone, the second step is to generate an 
expression vector. This is done by recombination of the gene on the entry clone with the final 
expression vector, performed by LR Clonase
®
. The different antibiotic resistances of the 
vectors allow fast clone selection. A large selection of Gateway expression vectors is 
available for the expression of native proteins as well as proteins fused with tags. One of the 
versions of the Gateway Cloning System is pENTR/TEV/D-TOPO. This version of the 
Gateway Cloning System includes the TEV recognition site on the N-terminus of the protein. 
The following expression destination vectors can be used in order to create the expression 
clones: pDEST-17 (conferring 6x histidine N-terminus), pETG-30A (conferring GST plus 6x 
histidine N-terminus), and pDEST-His-MBP (conferring MBP plus 6x histidine N-terminus), 
pETG-20A (conferring Trx plus 6x histidine N-terminus), and pTH34 (conferring GB1 plus 
6x histidine N-terminus), among others. It is important to highlight that the use of this 
methodology will result in the expression protein including extra residues on the N-terminus. 
For example, using the expression vector pDEST-17 that contains the 6xHis tag, the 
expressed and purified target protein will have 44 extra amino acids. After tag removal using 
TEV protease, the final construct will contain 4 extra residues on the N-terminus, GSFT. 
Tip 5 – Added fusion tags can be removed upon protease cleavage, but many of them can 
result in the addition of an extra amino acid sequence.  
Site-directed mutagenesis is a standard technique used to make point mutations, replace 
amino acids, and delete or insert single or multiple adjacent amino acids. Point mutations in 
which a single nucleotide is exchanged but the new codon specifies the same amino acid are 
called silent mutations. They basically code for the same amino acid, and are an easy way to 
avoid the "rare codons" that may decrease expression yield. This method uses the double-
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stranded DNA vector template containing the target gene and two complementary synthetic 
oligonucleotide primers, both containing the desired mutation. The primers are mixed with the 
DNA vector template and extended during PCR cycles performed by a high fidelity DNA 
polymerase. The PCR product is then treated with DpnI, an endonuclease that will digest the 
DNA template due to its high specificity to Dam methylated and hemimethylated DNA 
isolated from E. coli strains. The new copies of the DNA PCR product were never methylated 
and are thus not digested. The digested solution is then transformed into XL1-Blue super-
competent cells and subsequently subjected to sequencing analysis. 
Tip 6 – Use site-directed mutagenesis to create silent mutations of rare codons, increasing the 
expression yield. 
Protein expression 
 
Several host systems are available for protein production including fungi, plant, bacteria, 
insect, yeast and mammalian cells (Shatzman 1995). The choice of the expression system for 
the high-level production of recombinant proteins depends on many factors, including 
biological activity of the target protein, post-translational modifications, cell growth features, 
intracellular and extracellular characteristics, and expression levels. The many advantages of 
the use of Escherichia coli (E. coli) have ensured that it has remained a valuable organism for 
the high-level production of recombinant proteins; it is the easiest, quickest and cheapest 
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expression system (Tong, Yamamoto, and Tanaka 2008). Protein expression using the yeast 
expression system is also a good solution; however, for 
13
C labelling, which requires a correct 
promoter for the carbon source (Weinhandl et al. 2014), it can be an expensive solution 
compared with the E. coli expression system for isotopic proteins. A wealth of biochemical 
and genetic knowledge of E. coli has driven the development of a variety of strategies for 
achieving high-level protein expression. The major challenges for obtaining high protein 
yields at low cost involve several aspects such as expression vector design, gene dosage, 
transcriptional regulation (promoter), mRNA stability, translational regulation (initiation and 
termination), host design considerations, codon usage, and the fermentation factors available 
for manipulating the expression conditions (Jana and Deb 2005).  
Tip 7 – Expression of isotopically labelled proteins in E. coli is much cheaper as comparing to 
yeast due to carbon source costs.  
The expression condition should be tested once the expression system has been selected. 
Therefore, the best approach is to use parallel test expression strategies (Lesley 2009). A 
preliminary expression test can be performed using a small volume in order to find the best 
conditions to be reproduced in large volumes to obtain soluble recombinant protein. It is 
important to take the following factors into consideration for protein expression: culture 
medium, temperature, optical density, isopropyl β-D-1-thiogalactopyranoside (IPTG) inducer 
concentrations and induction time. A library of different E. coli strains possessing various 
properties that could be advantageous in the expression of a certain protein is available. 
Common examples are the E. coli strains BL21(DE3) (the standard version) or some variants 
such as BL21(DE3)pLysS, which encode the T7 lysozyme to decrease the background 
expression level of target genes under the control of the T7 promoter, but do not interfere with 
expression levels following induction by IPTG, Rosetta(DE3)  and Codon Plus for genes 
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containing rare codons, Origami(DE3) for proteins containing disulfide bridges, and 
Gold(DE3) for increasing expression yields.  
Depending on the research purpose the cells can be grown in different types of media: rich 
media, lysogeny broth (LB), 2x yeast extract and tryptone broth (YT), Terrific broth, NZY 
and the minimal media M9. When labelled protein is necessary, the M9 is supplemented with 
[C
13
] and [N
15
] sources. In order to increase the expression yield of isotopically labelled 
protein, one good solution could be the use of the Marley method (Marley, Lu, and Bracken 
2001). The cells transformed with the expression plasmid are initially grown in rich medium 
until high optical densities, and are then centrifuged and exchanged into an isotopically 
defined minimal media enriched with (15NH4)2SO4 (1 g/L) and (
13
C) glucose (4 g/L). Labelled 
protein can also be produced in commercially available and isotopically enriched rich media, 
e.g. Silantes. This could be particularly advantageous for the expression of deuterated labelled 
protein in terms of a simplified cell adaptation process. Small-scale test expression is the first 
step in the expression of the target protein; it is important to reproduce the expression 
conditions required for large-scale production as much as possible. 
Tip 8 – In some cases the isotopically labelled carbon and nitrogen sources may give different 
expression yields and protein solubility. Consider a small test expression using isotopically 
labelled nutrients. 
Zinc is essential for many cellular processes, including DNA synthesis, transcription, and 
translation, but an excess can be toxic (Babich and Stotzky 1978; Kindermann et al. 2005). In 
order to find the optimal amount of zinc additive, different trials should be performed using 
controlled minimal media instead of rich LB (Outten and O'Halloran 2001). The amount of 
zinc can be tested by comparing zinc-depleted cultures at a concentration range of 10 - 400 
µM of ZnCl2 and ZnSO4 addition.  
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Tip 9 – When working with a metalloprotein, the expression tests should be performed taking 
into account the concentration of the required metal. 
In order to avoid hundreds of different screening conditions, one can start with a couple of 
conditions and alter specific conditions if needed and according to the preliminary results 
obtained. Three different E. coli strains induced at a single optical density of 0.6, using a 
single IPTG concentration of 0.5 mM, three different expression temperatures (17, 30 and 
37ºC) and two expression times (4 h and 16 h) will result in 18 different conditions. In case of 
non-satisfactory results, one can try different E. coli strains, optical densities or IPTG 
concentrations. Cells should be harvested, disrupted and normalized to the final optical 
density. The presence of soluble protein is checked with sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). 
One important aspect of IDPs when running an SDS-PAGE is abnormal protein size. IDPs 
typically run on SDS-PAGE as though they exhibit a higher molecular mass. This aberrant 
migration occurs due to the different amino acid composition caused by the high acidic 
residue content of some IDPs (Armstrong and Roman 1993; Graceffa, Jancsó, and Mabuchi 
1992). 
Tip 10 – In some cases the isotopically labelled carbon and nitrogen sources may give 
different expression yields and protein solubility. Consider a small test expression using 
isotopically labelled nutrients. 
If all the trials to obtain soluble protein fail, the insoluble fraction can be recovered in the 
refolding process.  
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Protein purification 
 
The protein purification strategies rely on the biophysical and biochemical properties of each 
specific protein. The purification strategy could be summarized in three main steps (Figure 
5.1), which may or may not be performed depending on the required purity of the final 
sample. In the first step the target protein is isolated from the cells and protected from 
possible degradation. The main bulk of impurities could then be removed by heating, passing 
the lysate through ion exchange or affinity columns. In the final step the samples could 
undergo size exclusion or high-resolution chromatography for the removal of trace impurities. 
 
Figure 5.1.  Three step purification strategy 
The peculiar amino acid composition of IDPs will contribute to specific biophysical 
properties that are completely different from those of folded proteins. A set of preliminary 
experimental trials should be performed to learn which reagents might be present during the 
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purification, which must be avoided, and under which conditions the protein has to be stored. 
Designing the protein purification strategy for a new protein from scratch requires a 
preliminary bioinformatics study to predict several biochemical and biophysical 
characteristics as well as the study of previously published purification strategies (Hunt 2005). 
Several factors should be taken into account for both soluble and unsoluble proteins, 
including: ionic strength, pH, temperature, oxygen concentration, and protein concentration. 
For example, if the protein contains several free cysteine residues, anaerobic purification 
methods and the use of reducing agents may be required to avoid the formation of non-
physiological multimers and oligomers. The localization of the expressed protein within the 
cell (soluble in cytoplasm or periplasm, or present in inclusion bodies (IBs)) makes a strong 
contribution to the choice of the purification strategy (Linn 2009). In each case the isolation is 
performed in different ways. Assuming the protein was not excreted into the growth medium, 
cell lysis is the first step for protein purification. The disruption of the cells can be performed 
through several techniques, ranging from mechanical to detergent-based methods. For 
instance, the French press is an efficient method, though it heats the final lysate, while freeze-
thaw or enzymatic and detergent lysis are considered mild methods but less efficient. In the 
present work, the cell disruption was performed by sonication, which comprises pulsed, high 
frequency sound waves to mechanically agitate and lyse the cells. The isolation of proteins 
using sonication should be done carefully because the mechanical wave energy will heat the 
sample. To avoid sample warming, sonication should be performed using an ice bath and with 
short pulses, with intervals to allow the temperature to decrease. Sonication methods can be 
also performed inside an anaerobic chamber (glove box) for anaerobic purification strategies. 
If degradation of the protein target has been observed during the purification steps, different 
cocktails of protease inhibitors can be directly added to the lysis buffer.  
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IDPs are prone to degradation due to their intrinsically disordered properties, which make the 
amino acid chain fairly exposed and allow easy access to proteases. The use of protease 
inhibitor cocktails starting from the first step of protein purification may be a good solution to 
avoid IDP degradation. Working at low temperatures may also help decrease protease 
activity. Conversely, some IDPs are thermo-stable at high temperatures, which can be used as 
an initial purification step.  By warming the cell extract, several folded proteins including 
proteases will precipitate and can be easily separated by centrifugation. High temperature can 
cause some conformational changes in protein structure. Comparison of the pure protein 
sample obtained with and without heating should be performed by using circular dichroism 
(CD), dynamic light scattering (DLS) and nuclear magnetic resonance (NMR). Different 
temperatures and durations of sample exposure to the heat can be checked in order to find the 
optimal conditions where the IDP can be isolated without being damaged. 
Tip 11 – Check how thermo-stable your IDP is. It may be helpful for the purification steps. 
Once the protein fraction is isolated from the cells, the following purification step can be 
performed in a multitude of chromatography runs. The methodology should always be 
optimized to reach an efficient protocol in terms of yield, speed and costs. Among all the 
different chromatography techniques, we will describe the three most used ones: immobilised 
metal ion affinity chromatography (IMAC), ion exchange chromatography (IEX) and size 
exclusion chromatography (SEC).  
Immobilized metal ion affinity chromatography (IMAC) is currently the most used affinity 
technique exploiting the interaction between chelated transition metal ions (such as Zn
2+
 or 
Ni
2+
) and the side chains of specific amino acids (such as histidines) on the protein.  
 
149 
 
Tip 12 – Take advantage of the specific metal affinity of your protein in the choice of metal 
ions for IMAC. 
In basic terms, by using IMAC the target protein is tightly bound to the resin matrix and the 
impurities are washed out with increasing concentrations of imidazole, which acts as a 
competitive agent. At higher imidazole concentrations the target protein is eluted at an almost 
pure concentration (Block et al. 2009).  
Fused proteins can be separated by enzymatic digestion to cleave the tags. After tag cleavage 
the separation of tag and target protein can be accomplished by the second IMAC 
chromatography step. 
Tip 13 –To avoid imidazole during the IMAC protein elution process, an elution buffer with 
low pH could be used. 
IEX separates proteins on the basis of a reversible interaction between the polypeptide chain 
and a specific charge ligand attached to a chromatographic matrix. The isoelectric point (pI) 
of the target protein must be known. The sample is loaded in conditions that favour specific 
binding such as calibrated pH and low ionic strength salt concentration in order to enhance the 
interaction between the target protein and column matrix. The unbound impurities are washed 
out and the bound protein is eluted by changing the pH or ionic strength of the elution buffer. 
If the overall net charge of the protein is positive, a cationic IEX resin must be used, while if 
it is negative, an anionic IEX resin must be used. The buffer pH should be at least ± 1 unit 
different from the protein pI. 
SEC is a separation technique based on the hydrodynamic radius of the proteins. The column 
matrix is composed of precisely sized beads containing pores of given sizes. Larger proteins 
whose hydrodynamic dimensions are too big to fit inside any pore will only have access to the 
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mobile phase between the beads, and will be excluded as they will just follow the solvent flow 
and reach the end of the column before molecules of a smaller size. Proteins with smaller 
hydrodynamic dimensions will be drawn into the pores by diffusion, and have access to the 
mobile phase inside and between the beads. Therefore, smaller molecules will have a long 
distance to cross with several small retention times between the diffusion movements through 
the bead pores. Due to larger retention, smaller hydrodynamic molecules will elute last during 
the size exclusion separation. SEC can be used to separate proteins by size and shape, to 
exchange the buffer, and also to isolate protein mixtures and separate monomers, multimers or 
oligomers. In the case of folded proteins, it can also be used to determine the molecular mass 
by performing a molecular weight distribution analysis using available standards.  
Tip 14 - Hydrodynamic volume is one of the most important IDP biophysical parameters to be 
taken into consideration. 
SEC profiles are therefore dependent on the hydrodynamic volume of a protein, which is one 
of the most important and fundamental structural parameters of a protein molecule. 
Hydrodynamic volume is a prerequisite for an accurate classification of a protein 
conformation. It changes dramatically depending on whether the protein hydrodynamic 
dimension is compact like a folded protein or extended or partially extended like an IDP.  
Tip 15 – Comparison between the protein in native conditions and in the presence of a 
chaotropic agent allows a better understanding of how compact or extended the IDP 
hydrodynamic volume is. A comparative analysis can easily be addressed by SEC, CD, DLS 
and SAXS. 
Comparing two proteins with the same molecular weight, a well-folded protein will have a 
smaller hydrodynamic radius while an IDP will have a bigger one, behaving like a large 
folded protein with SEC. The SEC retention times for a folded protein and an IDP of the same 
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molecular mass will therefore be different and the IDP will elute first. SEC has been used for 
over three decades for the separation of unfolded and folded proteins (Gupta 1983). However, 
due to the particular characteristics of IDPs, SEC can be used for the analytical study of the 
conformational IDP properties in solution where the size and shape of molecules are the 
prime separation parameters (Uversky 2013).  SEC is usually performed as the last 
purification step for the preparation of high purity samples. A column of at least one meter 
high connected to a water thermostatic cooling system at 4ºC can be one of the best solutions 
for separating proteins with large hydrodynamic volumes. 
Tip 16 – When using analytical SEC for IDP studies, it is important to use standard IDPs such 
as α-synuclein in the same buffer conditions and temperatures as the target IDP. 
Purifying and refolding a protein from the insoluble fraction could be a challenging task and 
should be planned carefully. The strategy can be based on a previous bioinformatics analysis 
of the target protein combined with knowledge of the state-of-the-art of similar protein 
systems. Although many protocols have already been published and summarized in many 
reviews and book chapters (Burgess, Richard, and Murray 2009; Cowieson et al. 2006; 
Qoronfleh, Hesterberg, and Seefeldt 2007; Singh et al. 2005; Vincentelli et al. 2004), each 
protein is unique and requires a specific approach to the refolding process. 
The first step in refolding is solubilisation of the inclusion bodies. The solubilising 
agent/denaturant could be a chaotropic agent such as GuHCl and urea, or a detergent, and 
should be prepared in a controlled pH buffer. As for the other techniques already described in 
this work, the key concept for refolding is the systematic, parallel screening of multiple 
refolding conditions. Many additives may prove useful in refolding, but preventing 
aggregation and precipitation upon refolding is crucial for refolding at low protein 
concentrations. However, many variables in refolding should be controlled such as pH, 
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temperature, salt concentration, redox environment, and the presence of divalent metal ions.  
Redox agents 
Various redox pairs can be used including reduced and oxidized cysteine or glutathione as 
well as a reducing agent such as β-mercaptoethanol (BME), dithiothreitol (DTT) or tris (2-
carboxyethyl) phosphine hydrochloride (TCEP) to control the oxidation state of the protein. 
Since the cytoplasm of E. coli is highly reducing, most internal proteins are in the reduced 
state. If the protein contains both native disulfide bonds and free cysteines, the red/ox couple 
should be introduced into the refolding system in order to achieve optimal native disulfide 
bond formation, keeping native free cysteine residues. The free cysteines might induce 
incorrect disulfide bridge formation, especially at high protein concentrations. It could be 
advantageous to use a high concentration of the reducing agents, e.g. DTT and TCEP. 
Tip 17 - Consider the presence of disulfide bridges; the addition of a high concentration of the 
reductant can break them. 
Salt concentration 
To prevent undesirable hydrophobic interactions, the ionic strength of the solution could be 
increased by the addition of salt starting from 150 mM. 
pH 
In general the pH of the buffer should be at least one pH unit away from the pI in order to 
avoid a zero net charge of the protein, making it prone to precipitation. Some protocols rely 
only on a single pH refolding procedure (Coutard et al. 2012).  
Temperature 
Most refolding procedures are carried out at room temperature, which is low enough to 
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prevent thermal damage to the protein and high enough to increase the thermal motion of the 
molecules, an important aspect that allows them to reach their native state.  
Proline and arginine 
Proline is considered an osmoprotectant and has been found to be effective in increasing 
solubility both in vitro and in vivo (Ignatova and Gierasch 2006). Arginine can decrease 
aggregation by slowing the rate of protein–protein interactions by supramolecular assembly 
formation in solution. However, effective concentrations are reported to be in the range of 
0.5–1.0 M (Das et al. 2007).  
Glycerol 
Glycerol has been found to be an excellent refolding additive in many cases, as is usually used 
in the 5–30% range. 
Detergents 
Detergents can increase solubility, preventing aggregation during refolding. At low 
concentrations they bind weakly to exposed hydrophobic regions, preventing aggregation. 
As their concentration decreases they dissociate and allow reformation of the native structure. 
At high concentrations detergents are denaturants, but at low concentrations they can act as an 
artificial chaperone, promoting refolding without aggregation. One important aspect of 
detergents is the critical micelle concentration (CMC), the concentration at which micelles 
begin to form. The CMC value can be subject to buffer conditions such as pH and ionic 
strength. The CMC should be checked once for each buffer system as the manufacturer only 
provides a few values/conditions. Tables exist that report several values for each specific 
buffer condition (Brito and Vaz 1986; Jumpertz et al. 2011).  
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Once the protein of interest has been solubilised and all the refolding buffer conditions have 
been defined, refolding can be attempted. The refolding procedure is the removal of the 
denaturant agent, allowing the protein to reach its native state. Refolding can therefore be 
performed by dilution, multi-step dialysis, single dialysis, or with on-column refolding. 
Dialysis is one of the most used methods but it is time- and reagent-consuming. Affinity 
tagging of the recombinant protein can give the possibility of efficient and rapid on-column 
refolding and purification in a few steps just performing a washing series. If it doesn't 
precipitate inside the column, the refolded protein can be further eluted. Alternatively, 
dilution refolding can be performed by reverse dilution, the addition of refolding buffer to 
denatured protein with mixing between each addition, flash dilution, the addition of denatured 
protein to refolding buffer quickly, and drip dilution, the addition of denatured protein to 
refolding buffer very slowly, drop-by-drop, allowing refolding at low concentration.  
Several commercial products have been developed to help identify suitable refolding 
conditions such as EMD/Novagen's iFOLD kits, Pierce Biotechnology’s ProMatrixTM and 
AthenaES's QuickFold
TM
. 
Sample handling of intrinsically disordered proteins 
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The preparation of samples for different biophysical and biochemical characterisations should 
be prepared according to the technical limits of each technique/method.  
Stability  
Stability is one of the first conditions to check. One can try to perform the degradation test at 
various temperatures in order to understand if the protein is susceptible to degradation. 
Tip 18 – For the sake of protein long-term stability, work in the presence of protease inhibitor 
cocktails and at low temperatures during the purification steps. 
Anaerobic purification  
Proteins containing cysteine residues must be handled inside an anaerobic chamber under 
nitrogen atmosphere to prevent the oxidation of cysteine residues. All buffers used for the 
purification and sample preparation steps may be extensively degassed with nitrogen and 
argon. Reducing agents may be added to keep the cysteine residues reduced.  
Reducing agents  
Reducing agents can be exogenous sulfhydryl containing reducing agents such as DTT, or 
non-sulfhydryl reducing agents such as TCEP. The control of the redox state of the IDP target 
is crucial for a successful purification. The optimal reducing activity of DTT is in the 6.5 - 9.0 
pH range, while TCEP has a wide optimal reducing activity pH range spanning from 1.5 - 9.0. 
In some cases TCEP was reported to be more useful than DTT for protein sample preparation 
(Getz et al. 1999; Krezel et al. 2003).  
Once the protein sample is pure and stable conditions have been discovered, it is important to 
know its concentration to apply in different biophysical methods.  
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Methods of the protein concentration measurements  
Ultraviolet (UV)–visible spectroscopy applied to the protein research field can be used for 
many applications including detection of eluting components in high performance liquid 
chromatography (HPLC), the determination of the oxidation state of a metalloprotein centre 
of a cofactor, as well as the determination of the maximum absorbance of proteins and DNA 
for measurement of their concentrations. DNA quantification is based on purine and 
pyrimidine absorption, which is maximum around 260 nm. Proteins contain aromatic amino 
acid residues, which absorb light in the UV-range with absorption maxima around 280 nm. 
These amino acids are tryptophan (Trp), tyrosine (Tyr), and phenylalanine (Phe). The Trp, 
Tyr, and Phe absorption spectra of IDPs can be compromised as typically IDPs are depleted 
of these residues (Dunker et al. 2001).  
The concentrations can be calculated using the Beer-Lambert law, A = εcl, where A is the 
absorbance value at the chosen wavelength, c is the sample concentration (M) and l is the 
length of the light path through the sample (cm). The absorption spectrum of a protein is 
usually normalized to a concentration unit and cell width, and thus depends on the protein 
specific molar absorption coefficient ε and the measured wavelength 𝜆 absorption values. The 
theoretical molar extinction coefficient can be calculated, for example using the 
ExPASyProtparam
9
 tool (Gasteiger et al. 2005).  
Tip 19 - Some reagents used during the purification procedures such as imidazole or DTT 
exhibit absorbance at 280 nm. Remember to use the blank sample containing the same 
concentration of these reagents that is present in your sample. 
When the IDP doesn’t contain any aromatic residues, a refractometer instrument can be a 
good option for measuring protein concentration. This method is very sensitive to buffer 
                                                          
9 http://web.expasy.org/ protparam/ 
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conditions, so a standard curve should be created in the exact same buffer as the protein of 
interest. The preparation of a similar buffer will not work. The last step dialysis buffer, or 
even better the flow-through buffer, should be used when concentrating a pure protein sample. 
The same buffer should be used for the preparation of the bovine serum albumin (BSA) or 
lysozyme solutions in order to create a standard curve measured on the refractometer 
instrument. The target protein concentration can then be measured with high accuracy by 
interpolation. 
Tip 20 – A refractometer is very useful for IDPs that lack aromatic residues, but a standard 
curve should be created with exactly the same buffer as the one of the target IDP. 
Complementary biophysical techniques 
NMR is known as the best technique to study IDPs at atomic level, providing detailed 
residue-specific information. However, it is useful to complement the information obtained 
from NMR with other biophysical methodologies to better understand all kinds of function-
related transient, short, and long-range structural organisations. 
Depends on the specific type of information, needed to complete NMR data, different 
biophysical methods can be implemented. Among many various techniques, mass 
spectrometry (MS), Small Angle X-ray Scattering (SAXS), Circular Dichroism (CD) as well 
as Dynamic Light Scattering (DLS) are  the excellent complementation of NMR data. In this 
section we will focus our attention on IDP sample preparation for different biophysical 
techniques. 
Mass spectrometry (MS) is an important emerging method for the protein characterization. 
The two primary methods for soft ionization of whole proteins are electrospray ionization 
(ESI) and matrix – assisted laser desorption/ionization (MALDI) (Romanova et al. 2009). 
They are strategies that can be used to retrieve accurate molecular weight measurements, 
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determine the purity of a sample, verify amino acid substitutions, detect post-translational 
modifications, calculate the number of disulphide bridges, analyze  intermolecular 
interactions (e.g. protein-protein binding). Application of hydrogen-deuterium exchange mass 
spectroscopy can provide valuable information about localization of flexible regions and  
protein folding  (Bobst and Kaltashow, 2012). Ion – mass spectrometry (IMS-MS) can be 
successfully applied for the identification of different aggregated assemblies and 
characterization of various conformation forms of the protein, which is especially important in 
terms of IDPs (Vlad et all 2012). This technology has the potential to separate and discern 
different conformational families even for IDPs, that the conformational properties of 
different forms of the same protein can be compared and structural events taking place during 
the transition from co-populated conformations can be monitored, giving interesting insights 
into their respective conformational behavior patterns (Knapman et al. 2013). 
 
Tip 21 – Use MS as one of the complementary techniques to characterize the different 
conformational states of IDPs. 
CD is an excellent tool that allows the quick determination of secondary structure and folding 
properties (e.g. arrangement of peptide bonds in secondary structure elements such as helices 
and strands) of proteins or nucleic acids in solution and is based on differential absorption of 
left- and right-handed circularly polarized light.  
In proteins the major optically active groups are the amide bonds of the peptide backbone 
(peptide bond: absorption below 240 nm, aromatic amino acid side chains: absorption in the 
range 260 to 320 nm, and disulphide bonds: weak broad absorption bands centred around 260 
nm), typically disposed in highly ordered arrays such as alpha-helices or beta-pleated sheets. 
All alpha- helices proteins display a strong positive band (at 191–193 nm) and an intense 
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negative band with two peaks at 208 and 222 nm. Beta-sheets proteins have a negative band at 
210–225 nm and a stronger positive band at 190–200 nm. Instead unordered peptides and 
denatured proteins have a strong negative band at 195–200 nm (Martin and Schilstra, 2008). 
IDPs present particular CD characteristics different from those of folded proteins and also 
different from random coil polypeptides, presenting specific conformational preferences and 
thus revealing partially populated secondary content. CD allows to analyze stability as well as 
alterations of these conformation under different conditions e.g. changes in pH, temperatures, 
salt concentrations and addition of the cosolvents.  
Special care should be devoted to sample preparation. All samples prepared for CD 
measurements should be of the highest possible purity due to the fact that contaminations lead 
to deceptive results. The high concentrations of chloride and nitrate, as well as common 
chelators (ethylene glycol tetraacetic acid (EGTA)/ethylenediaminetetraacetic acid (EDTA)) 
and reducing agents (dithiothreitol and 2-mercaptoethanol) should be avoided in the buffer. It 
is also not advisable to use certain organic solvents (dioxane, dimethyl sulfoxide (DMSO)) 
and some biological buffers such as HEPES, PIPES, and MES. If the IDP target is oxygen 
sensitive, anaerobic conditions should be established. 
The CD data can be fitted using the secondary structure estimation program K2D3
10
 (Louis-
Jeune, Andrade-Navarro, and Perez-Iratxeta 2012).  
Tip 22 – CD allows the determination of whether or not a purified protein is folded and how 
sample conditions affect its conformation or stability. 
Dynamic Light Scattering (DLS), also known as Photon correlation spectroscopy or Quasi-
elastic light scattering is a technique which can be used to determine such molecular 
                                                          
10 http://www.ogic.ca/projects/k2d3/ 
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parameters such as size, molar mass, and intermolecular interactions, which are important to 
identify and characterize intrinsically disordered proteins (IDPs). Coupled together with 
chromatography system it provides also information about aggregation state of the proteins.  
In DLS light intensity fluctuations taking place at microsecond or millisecond scales are 
measured. Those fluctuations are a measure of the diffusion constant (Brownian motion) of 
the molecules and are related to the hydrodynamic radius (RH) of a molecule, also known as 
the Stokes radius. Measured RH reflects the apparent size adopted by the solvated tumbling 
molecule and thus is possible to monitor expansion or compaction of protein molecules. This 
is especially important for IDPs, which can be recognized and characterized by comparing the 
measured RH radii with those calculated for particular reference states, such as the compactly 
folded or the fully unfolded states. 
Tip 23 - A useful procedure to analyse the basic conformational type of a protein through 
DLS is to utilize IDP like protein standard e.g. α-synuclein or a protein in the compactly 
folded globular state under the same conditions as the target protein in order to compare the 
measured Stokes radius.  
Essential point in sample preparation for DLS measurements is removal of the interfering dust 
particles, by e.g. filtration of protein solution. Is important to remove unwanted scattering 
events that will exclude coherence and destroy determinations of the diffusion coefficient and 
therefore size of the sample of interest. 
Tip 24 – The use of DLS attached to a fast protein liquid chromatography (FPLC) with SEC 
system might be applied for the investigation of the aggregation state of the IDPs, as well as 
efficient separation of their different assemblies such as oligomers. 
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Although DLS allows an easy and quick way to determine the value of the hydrodynamic 
Stokes radius (RH), obtainment of the geometric radius of gyration (Rg) through this technique 
is usually hampered by an excessively small size of the protein. This limitation can be 
overcome by utilization of SAXS. The ratio of Rg and RH (Rg/RH) provides useful shape 
information about a protein molecule, being the most informative parameter comparing SAXS 
and DLS data for the same IDP measured at the same buffer, temperature and concentration 
conditions.  
Tip 25 – Among many parameters that describe a molecule’s size and shape, RH is the most 
important information that can be obtained from DLS measurements of IDPs. A comparison 
with Rg from SAXS should be made.  
Small-angle X-ray scattering (SAXS), as one of the method complementary to NMR, provide 
low-resolution structural characterization of biological macromolecules in solution. In a 
SAXS experiments, samples containing dissolved proteins are exposed to an X-ray bean and 
the scattered intensity is recorded by a detector as a function of the scattering angle 
(Petoukhov and Svergun 2013). 
The major advantage of the method lies in its ability to provide structural information about 
partially or completely disordered systems. SAXS mostly contributes to obtain information 
about the IDPs hydrodynamic behavior and topology of the polypeptide chain. This 
techniques is also employed for the validation of structural models, analysis of oligomeric 
states, and the estimation of volume fractions of components in mixtures.. 
Tip 26 – Many IDPs are prone to aggregate, making SAXS measurements a challenging task. 
The sample preparation conditions may need to be redesigned according to the SAXS 
instrumentation capabilities. 
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SAXS not only provides shapes, oligomeric states, and quaternary structures of folded protein 
complexes, but also allows for the quantitative analysis of flexible systems. This fact can be 
successfully used to study the conformational flexibility of IDPs (Bernadó and Svergun 
2012a; Bernadó et al. 2007) and allows the exploration of different protein conformations in 
response to variations in external conditions such as  buffer composition, ionic strength, pH, 
and temperature. Temperature measurements are particularly useful for studies of the 
thermodynamic characteristics of IDPs. However, in order to avoid radiation damage, SAXS 
measurements are usually made below room temperature. 
Sample preparation for SAXS experiments should follow the standard guidelines (Jacques et 
al. 2012). SAXS experiments typically require a highly pure, monodisperse protein solution in 
a concentration range from 1-10 mg/ml in order to fulfil the condition of a “dilute” solution. 
The concentrations must be determined accurately as it is necessary to appropriately 
normalize the scattering data and thus to estimate the effective molecular mass of the solute. 
If the sample is aggregated, the scattering data will be difficult or even impossible to interpret. 
A typical sample volume required for each single measurement depends on the SAXS station 
and a volume of about 50 µl is typically required for each single measurement. Each SAXS 
experiment at a given condition should be prepared in at least three different concentrations. 
Each condition such as buffer, ionic strength, pH, and temperature therefore requires 1-2 mg 
of purified sample. The concentration range can be prepared by dilution of a concentrated 
stock, if it is known that the protein is not affected by aggregation. In case the protein tends to 
aggregate it is better to prepare a stock of diluted protein sample and then prepare the 
concentrated samples immediately before the SAXS experiments. Is important to note that for 
each experiment at a given condition, the scattering of the buffer is also measured by SAXS 
for further subtraction. Thus the buffer composition must precisely match the composition of 
the sample. Even a small mismatch in the chemical composition of the solvent between the 
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buffer and the sample may lead to difficulties during background subtraction. The best 
approach is to use the dialysis buffer in which the protein was prepared.  
Different strategies and software packages are available for the analysis of the SAXS data. 
One example is the protocols based on the use of the program ATSAS, which is in use at the 
German Electron Synchrotron DESY (Konarev et al. 2006; Petoukhov et al. 2012). The 
ATSAS package also includes the Ensemble Optimization Method (EOM), which has been 
developed as a strategy for the structural characterization of IDPs (Bernadó et al. 2007). This 
program takes into consideration an infinite amount of conformations that are in fast 
equilibrium exchange and is especially useful for flexible systems.  
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Chapter 4   Conclusions 
This thesis is focused on expression, purification, as well as structural and biochemical 
characterization of potential amyloidogenic proteins: Aβ peptides and hSOD. Both of these 
proteins very often misfolds and evades normal clearance pathways, what results in 
pathogenic process in which the protein aggregates progressively into intracellular and/or 
extracellular deposits. The consequence of aggregation of Aβ peptides and hSOD in 
characteristic patterns and locations is Alzheimer’s disease (AD) and amyotrophic lateral 
sclerosis (ALS), respectively. The molecular mechanism of both these neurodegenerative 
disorders is still unclear and unveiled and until now no efficient treatments are available for 
AD and ALS. 
A detailed structural and functional characterization of fibrillar assemblies as well as 
the various prefibrillar intermediates is crucial for understanding Aβ precise mechanism 
aggregation pathways and identifying toxic Aβ species. Therefore we focused on the 
investigation of different Aβ assemblies. Section 3.1 show application of a novel method 
defined as sedimented solutes NMR (SedNMR) to detailed structural characterization of 
oligomeric and prefibrillar assemblies. We proved that SedNMR allows to trapped Aβ 
aggregates in a fully hydrated environment without adding cosolvents or interaction partners, 
therefore providing a unique way to access the formation kinetics and structural features of 
these species with reduced perturbations. Obtained qualitative picture of intermediates 
structural features provide evidence that these prefibrillar assemblies already contain β-strand 
structures (especially most hydrophobic regions), but with different supramolecular 
organizations and reduced structural order and periodic symmetry and demonstrate probable 
pathway from these fibril precursors to terminal fibrillar states. Section 3.2 is focused on high 
resolution structural characterization of AβM40 and AβM42 mixture fibrils prepared in 
different molar ratio related to the pathological conditions. Optimized sample preparation is 
crucial for obtaining high resolution SSNMR spectra on these biomacromolecular assemblies 
and only high homogeneity (conformational homogeneity and local order of packing) of the 
samples permits a full assignment of SSNMR signals. The collective data obtained through 
SSNMR demonstrate that a change in the AβM42:AβM40 ratio induces differences in 
conformational plasticity of the peptide mixtures, that clearly shown that these two species 
interact and change each other’s dynamic behaviour. The new structural model derived from 
high resolution data and the identification of AβM40:AβM42 reciprocal association in the 
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fibrils should broaden our understanding of exacts structural properties, as well as interaction 
and behaviour of these components. Finally structural information of Aβ amyloid fibril 
formation is fundamental for the development of diagnostics and therapeutic approaches, and 
in addition might be valuable for elucidating fundamental mechanism of proteins folding and 
assembly.  
Although the causes of motor neuron death in ALS are poorly understood, a prominent 
hypothesis for SOD1-linked familial ALS involves the formation of protein aggregates 
containing misfolded hSOD1 as the main component in amyloid-like deposits. Therefore 
many studies have been focused on the investigation of the therapeutic strategies aimed to 
prevent SOD1 pathogenic aggregation. One of the rational drug design was established based 
on previous knowledge on the chemical mechanism of apo SOD1 aggregation and the 
chemical reactivity of cisplatin that selectively binds to solvent exposed Cys-111 and strongly 
inhibits process of oligomerization. Section 3.3 demonstrates attempt of reverting side effects 
caused by cisplatin, since clinical use of this chemotherapeutic agent is severely limited by the 
development of neurotoxicity and others undesirable effects. We proposed that chemically 
synthesized new molecues, ADM_09 and ADM_12 are possible candidates in suppression of 
neuropathic pain. Although the actual mechanism of action of these molecules has yet to be 
established, the findings reported in this work open the way to the development of a new 
generation of compounds remarkably effective in the treatment of cisplatinum-induced 
neuropathy without eliciting the most common negative side-effects, what could open a door 
toward a novel therapeutic strategies in ALS. 
Section 3.4 and section 3.5 are book’s chapters and are integral part of “Intrinsically 
disordered protein by NMR” book. Section 3.4 comprise history of the discovery of beta 
amyloid protein and it’s proteolytic biogenesis, polymorphism widely observed for Aβ 
amyloidal aggregates in vitro, overview of functional polymorphism and structural models of 
amyloidal fibrils, review of the methods of immobilization and investigation of amyloidal 
intermediate species, as well as association between neurotoxicity and different ratios of 
Aβ40 to Aβ42, which provide the stability to neurotoxic species. Last subsection contains 
materials and methods, as well as practice advice about handling with Aβ samples. Section 
3.5 contains such issue as genome browsing and bioinformatics analysis, expression plasmid 
generation and different approaches of protein expression and purification. Last subsection is 
devoted to different methodologies with special highlight for tips and tricks helpful to 
overcome common drawbacks/barriers usually faced when working with IDPs. 
